<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gastric cancer: Pathology and molecular pathogenesis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gastric cancer: Pathology and molecular pathogenesis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gastric cancer: Pathology and molecular pathogenesis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory Lauwers, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Priyanthi Kumarasinghe, MBBS, MD, FRCPA, Dip.Cytopath (RCPA)
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard M Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2115175176">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric adenocarcinomas represent a clinically, biologically, genetically, and microscopically heterogeneous group of malignant epithelial tumors resulting from various environmental and genetic causes.
        </p>
        <p>
         This topic will discuss the pathology and molecular pathogenesis of gastric cancer. The epidemiology, risk factors, clinical features, diagnosis and staging of gastric cancer are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2616.html" rel="external">
          "Epidemiology of gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2617.html" rel="external">
          "Risk factors for gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2513.html" rel="external">
          "Clinical features, diagnosis, and staging of gastric cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2593190214">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Worldwide, gastric cancer is the fourth most common cancer, accounting for 6 percent of total cancer incidence, and is the third leading cause of death, accounting for 8 percent of cancer-related deaths, according to data from the World Health Organization (WHO)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fgco.iarc.fr%2Ftoday%2Fhome&amp;token=o1j24x8yqbCigYycIC6ni4B7VDe7Hz17hJNfy5f8gT3%2F1GKAFN45f%2BlZyQqB2Xd7&amp;TOPIC_ID=119517" target="_blank">
          GLOBOCAN database
         </a>
         . Despite a steady decline in the rates of incidence and mortality observed worldwide for several decades, this trend has been lessened, particularly in the non-Hispanic White population [
         <a href="#rid1">
          1,2
         </a>
         ]. In this group, particularly for females, the risk may be related to autoimmune gastritis [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2616.html" rel="external">
          "Epidemiology of gastric cancer", section on 'Mortality'
         </a>
         .)
        </p>
        <p>
         The distribution of gastric cancer is markedly varied worldwide, with the areas presenting the highest rates of incidence (&gt;60 per 100,000 males) found in Eastern Asia (Korea), Eastern Europe, and Central and Latin America. Conversely, some geographic zones have low incidence rates (&lt;15 per 100,000 population), such as North America, Northern Europe, and Africa [
         <a href="#rid3">
          3
         </a>
         ]. Morphologic differences also align with this epidemiologic diversity. The intestinal type of adenocarcinoma is predominant in high-risk areas, while the diffuse type is relatively more common in low-risk areas. Also, distal cancers of the antrum and pylorus tend to be most common in high-risk countries, while cancers of the cardia are most common in Western nations of low incidence [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2616.html" rel="external">
          "Epidemiology of gastric cancer", section on 'Regional variation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3541845068">
         <span class="h2">
          Sex and age distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         Males and females are not equally affected; incidence rates are approximately twofold higher in males than in females. As an example, in data from the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fgco.iarc.fr%2Ftoday%2Fdata%2Ffactsheets%2Fcancers%2F7-Stomach-fact-sheet.pdf&amp;token=FxKq6fqndswJ5AiFkW5q1UMdSINuEaAc7R9Pe1K%2BKWoKiVQvxG9tRFHu67IgM2VzUPrHuPjEDcSR6a%2FpUgKfilkybuc2h83Ze7q0ez4ZBG4%3D&amp;TOPIC_ID=119517" target="_blank">
          GLOBOCAN database
         </a>
         , the cumulative risk for gastric cancer to age 74 for males versus females in 2018 was 1.87 versus 0.79 percent. However, in younger individuals, the male:female ratio is approximately equal or even shows a female predominance [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         Gastric carcinoma is extremely rare in persons under the age of 30 years [
         <a href="#rid3">
          3
         </a>
         ]. In younger individuals, poorly cohesive diffuse-type tumors are predominant [
         <a href="#rid7">
          7-9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2616.html" rel="external">
          "Epidemiology of gastric cancer", section on 'Incidence'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1847213067">
         <span class="h1">
          ETIOLOGY AND RISK FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H565388549">
         <span class="h2">
          Helicobacter pylori
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Helicobacter pylori
         </em>
         infection plays an important role in gastric carcinogenesis. It is estimated that at least 89 percent of all non-cardia  (
         <a class="graphic graphic_figure graphicRef79793" href="/z/d/graphic/79793.html" rel="external">
          figure 1
         </a>
         ) gastric cancers are caused by
         <em>
          H. pylori
         </em>
         [
         <a href="#rid10">
          10
         </a>
         ]. Given the central role that
         <em>
          H. pylori
         </em>
         has in the development of gastric cancer [
         <a href="#rid4">
          4
         </a>
         ], in 1994, the International Agency for Research on Cancer (IARC) recognized chronic infection with
         <em>
          H. pylori
         </em>
         , commonly acquired during early childhood, as a primary cause of gastric adenocarcinoma [
         <a href="#rid11">
          11
         </a>
         ]. Left untreated,
         <em>
          H. pylori
         </em>
         infection initiates a slow carcinogenic process, developing over decades and eventually leading to antral-predominant chronic active gastritis and ultimately to multifocal atrophic gastritis, which is a risk factor for intestinal and, less commonly, diffuse gastric adenocarcinomas [
         <a href="#rid12">
          12
         </a>
         ]. The epidemiologic data linking
         <em>
          H. pylori
         </em>
         to gastric cancer are reinforced by animal models of
         <em>
          H. pylori
         </em>
         infection, in particular in Mongolian gerbils [
         <a href="#rid13">
          13,14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2514.html" rel="external">
          "Association between Helicobacter pylori infection and gastrointestinal malignancy", section on 'Gastric cancer'
         </a>
         .)
        </p>
        <p>
         Nevertheless, only a small minority of individuals infected with
         <em>
          H. pylori
         </em>
         develops gastric cancer, and it is thought that modulation of the effects of chronic infection by genetic susceptibility, environmental factors, and
         <em>
          H. pylori
         </em>
         bacterial strain differences all influence the evolution into a neoplastic or nonneoplastic process [
         <a href="#rid15">
          15-17
         </a>
         ].
         <em>
          H. pylori
         </em>
         virulence factors that vary between strains, namely the cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA), appear to influence the pathogenicity of the bacteria and the risk of gastric precancerous lesions and adenocarcinoma [
         <a href="#rid18">
          18
         </a>
         ]. The variation in virulence factors relates to higher degrees of mucosal inflammation and progression of precancerous lesions [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15.html" rel="external">
          "Pathophysiology of and immune response to Helicobacter pylori infection", section on 'Bacterial strain differences'
         </a>
         .)
        </p>
        <p>
         Aspects of host genetic susceptibility that affect the inflammatory response also impact the gastric cancer risk associated with
         <em>
          H. pylori
         </em>
         infection. As an example, polymorphisms in genes encoding interleukin 1 (IL-1) beta, the IL-1 receptor antagonist, tumor necrosis factor (TNF) alpha, and IL-10 have been implicated in the initiation and modulation of the inflammatory response and have been associated with susceptibility to carcinogenesis [
         <a href="#rid17">
          17,21-25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15.html" rel="external">
          "Pathophysiology of and immune response to Helicobacter pylori infection", section on 'Inflammatory response'
         </a>
         .)
        </p>
        <p>
         Gland-forming adenocarcinomas (ie, those of the tubular, papillary, mucinous, and mixed types) are causally related to
         <em>
          H. pylori
         </em>
         . The poorly cohesive histologic type (corresponding to Lauren's classification of "diffuse gastric cancer") is more likely to result from hereditary characteristics modulated by environmental influences, while
         <em>
          H. pylori
         </em>
         is probably limited to a subset of sporadic cases in this subgroup [
         <a href="#rid5">
          5,26,27
         </a>
         ]. (See
         <a class="local">
          'Hereditary diffuse gastric cancer'
         </a>
         below.)
        </p>
        <p>
         In contrast to non-cardia gastric cancers, there appears to be a strong
         <strong>
          inverse
         </strong>
         relationship of
         <em>
          H. pylori
         </em>
         with cancers of the esophagogastric junction (EGJ) and cardia, and their precursor lesion, Barrett's esophagus [
         <a href="#rid28">
          28-30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3349434706">
         <span class="h3">
          The preneoplastic cascade
         </span>
         <span class="headingEndMark">
          —
         </span>
         While
         <em>
          H. pylori
         </em>
         infection usually starts in infancy or early childhood, there is a long latency period, and cancers are clinically diagnosed four or more decades later. During this period, a prolonged precancerous process takes place, represented by a "cascade" of sequential histopathologic stages: chronic active nonatrophic gastritis, multifocal atrophic gastritis, intestinal metaplasia (complete, then incomplete), dysplasia, and invasive carcinoma in a high-incidence area [
         <a href="#rid15">
          15,31
         </a>
         ]. The risk of gastric cancer in patients with these various premalignant lesions was addressed in two population-based studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a nationwide cohort study from the Netherlands, atrophic gastritis, intestinal metaplasia, mild-moderate dysplasia, and severe dysplasia were associated with annual incidences of gastric cancer of 0.1, 0.25, 0.6, and 6 percent, respectively [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another cohort study from Sweden, among patients who undergo gastroscopy with biopsy for clinical indications, approximately 1 in 85 with gastritis, 1 in 50 with atrophic gastritis, 1 in 39 with intestinal metaplasia, and 1 in 19 with dysplasia will develop gastric cancer within 20 years [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Endoscopic surveillance strategies for those with gastric intestinal metaplasia, atrophic gastritis, and dysplasia are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16636.html" rel="external">
          "Gastric intestinal metaplasia", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/30.html" rel="external">
          "Metaplastic (chronic) atrophic gastritis", section on 'Endoscopic surveillance in selected patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4217598857">
         <span class="h4">
          Nonatrophic gastritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first stage of chronic
         <em>
          H. pylori
         </em>
         infection is a nonatrophic gastritis, which predominates in the antrum and is characterized by a dense, band-like infiltrate of lymphocytes, macrophages, and plasma cells  (
         <a class="graphic graphic_picture graphicRef53009" href="/z/d/graphic/53009.html" rel="external">
          picture 1
         </a>
         ). Occasionally, lymphoid follicles are formed. The term "activity" refers to the presence of focal acute inflammation in a background of chronic gastritis. The presence of polymorphonuclear neutrophils (PMNs) correlates closely with active colonization of the gastric lumen by
         <em>
          H. pylori
         </em>
         organisms.
        </p>
        <p>
         It is important to emphasize that nonatrophic antral gastritis, which is the predominant finding in patients with an
         <em>
          H. pylori
         </em>
         -associated duodenal peptic ulcer, is not related to an increased cancer risk. (See
         <a class="medical medical_review" href="/z/d/html/17.html" rel="external">
          "Association between Helicobacter pylori infection and duodenal ulcer"
         </a>
         .)
        </p>
        <p>
         In a subset of patients, atrophy with intestinal metaplasia will develop, beginning a sequence of events that may culminate in adenocarcinoma; the rate of progression to atrophic gastritis/intestinal neoplasia in large cohorts is 0.1 to 0.9 percent [
         <a href="#rid34">
          34
         </a>
         ]. The prevalence of intestinal metaplasia in the community among
         <em>
          H. pylori
         </em>
         -affected patients varies significantly from region to region, with a possible correlation between intestinal metaplasia prevalence and the availability of tobacco [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2883353684">
         <span class="h4">
          Atrophic gastritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrophic gastritis is an advanced stage characterized by multifocal loss of the original gastric glands  (
         <a class="graphic graphic_picture graphicRef131611" href="/z/d/graphic/131611.html" rel="external">
          picture 2
         </a>
         ). In most patients, active gastritis does not lead to gland loss, but when it does, it is the first histopathologic lesion of the preneoplastic cascade related to
         <em>
          H. pylori
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/30.html" rel="external">
          "Metaplastic (chronic) atrophic gastritis"
         </a>
         .)
        </p>
        <p>
         Several classifications of chronic gastritis have been developed in an attempt to combine topographic, morphologic, and etiologic information into a reporting system including both grading and staging of gastritis, while other systems, like the Operative Link for Gastritis Assessment (OLGA), rank the histologic phenotypes of gastritis along a scale of increasing mucosal atrophy, with high-stage disease being associated with a high risk of gastric cancer [
         <a href="#rid36">
          36
         </a>
         ]. There is no one universally accepted classification system that is prognostically useful. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/29.html" rel="external">
          "Gastritis: Etiology and diagnosis", section on 'Etiology and classification'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4238016116">
         <span class="h4">
          Intestinal metaplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multifocal atrophy involving the gastric mucosa may be followed by the development of glands presenting an intestinal phenotype. In intestinal metaplasia, the original gastric mucins, which have a neutral pH, are replaced by acid mucins, which may be sialic or sulfated [
         <a href="#rid37">
          37,38
         </a>
         ]. Using a combination Alcian blue (AB) and high-iron diamine stain (not available anymore because of its toxicity) and immunohistochemistry (IHC), gastric intestinal metaplasia has been classified, based on the types of mucins expressed, into the following types (see
         <a class="medical medical_review" href="/z/d/html/16636.html" rel="external">
          "Gastric intestinal metaplasia"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type I (complete) intestinal metaplasia expresses only sialomucins and expresses MUC2 (an intestinal mucin), while gastric mucins are either decreased or absent (MUC1, MUC5AC, and MUC6).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type II (incomplete) intestinal metaplasia expresses a mixture of gastric (neutral) mucins and intestinal sialomucins.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type III (incomplete) intestinal metaplasia, which is the least common, is characterized by the presence of columnar mucous cells containing sulfomucins. Incomplete metaplasia coexpresses intestinal mucin and gastric mucins.
        </p>
        <p>
        </p>
        <p>
         In addition to the pattern and type of mucin expression, currently used classifications for gastric intestinal metaplasia also take into consideration the presence of Paneth cells (complete metaplasia) or crescent architecture changes, dedifferentiation, and the degree of absence of Paneth cells (incomplete metaplasia). Complete-type intestinal metaplasia displays goblet cells and absorptive cells with a brush border and shows decreased/absent expression of gastric mucins (MUC5AC and MUC6) and expression of MUC2 (an intestinal mucin) [
         <a href="#rid39">
          39
         </a>
         ]. Incomplete intestinal metaplasia displays goblet and columnar nonabsorptive cells without a brush border and coexpression of gastric mucins and MUC2.
        </p>
        <p>
         Morphologically, the first metaplastic glands seen in chronic
         <em>
          H. pylori
         </em>
         infection phenotypically resemble those of the small intestine, with eosinophilic absorptive enterocytes with a brush border alternating with mucus-producing goblet cells (ie, type I, complete, or small intestinal-type metaplasia  (
         <a class="graphic graphic_picture graphicRef81064" href="/z/d/graphic/81064.html" rel="external">
          picture 3
         </a>
         )). These changes are thought to be triggered by the loss of the acid-secreting parietal cells.
        </p>
        <p>
         More advanced stages adopt characteristic changes that are more similar to colonic phenotype, with the glands becoming lined by irregular goblet cells (type III, incomplete types IIA/II, and IIB/III incomplete colonic metaplasia  (
         <a class="graphic graphic_picture graphicRef77310" href="/z/d/graphic/77310.html" rel="external">
          picture 4
         </a>
         )) [
         <a href="#rid40">
          40,41
         </a>
         ]. More advanced stages of metaplasia increase the risk of gastric cancer [
         <a href="#rid42">
          42,43
         </a>
         ]. As an example, a systematic review of 10 observational studies showed that the risk of gastric cancer was 4- to 11-fold higher among those with incomplete metaplasia, compared with either complete metaplasia or the absence of incomplete type metaplasia [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Incomplete metaplasia is frequently detected around early gastric adenocarcinomas. Some consider colonic metaplasia to represent an early stage of dysplasia, deserving closer endoscopic surveillance than type I (small intestinal) metaplasia [
         <a href="#rid41">
          41,44,45
         </a>
         ]. The metaplastic changes are first seen at the junction of the antrum and the corpus mucosa (the location of the loss of acid-secreting parietal cells, oxyntic atrophy), especially in the area of the incisura angularis. Over time, the foci of metaplasia become larger and more numerous, extending to the antrum as well as to the corpus of the gastric mucosa. The larger the atrophic and metaplastic area, the greater the cancer risk.
        </p>
        <p>
         Corpus-predominant gastritis with multifocal gastric atrophy with intestinal metaplasia and hypo- or achlorhydria develops in approximately 1 percent of subjects infected with
         <em>
          H. pylori
         </em>
         . As a consequence of the elevation in gastric pH, a change in the gastric flora is observed, with colonization by anaerobic bacteria responsible for the formation of carcinogenic nitrosamines [
         <a href="#rid21">
          21,46
         </a>
         ]. Hypochlorhydria and low levels of pepsinogen I (produced by the chief cells of the corpus) and gastrin [
         <a href="#rid21">
          21
         </a>
         ] (produced by antral G cells) can be measured in the serum and can be used as an indicator of gastric atrophy and cancer risk [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Multiple studies have indicated a positive correlation between the degree of incomplete intestinal metaplasia, the extent of intestinal metaplasia overall, and the risk of gastric carcinoma [
         <a href="#rid37">
          37,44,45,48,49
         </a>
         ]. However, not all studies have been positive [
         <a href="#rid50">
          50-52
         </a>
         ], and there is little genetic mutational evidence to implicate intestinal metaplasia as a true direct precursor of gastric cancer.
        </p>
        <p>
         Another pattern of metaplasia is described, termed "spasmolytic polypeptide-expressing metaplasia" (SPEM), which strongly expresses trefoil factor family 2 (TFF2, previously designated spasmolytic polypeptide) and is associated with atrophy of the oxyntic mucosa. SPEM has also been termed "pseudopyloric metaplasia," and it has a strong association with both chronic infection with
         <em>
          H. pylori
         </em>
         and gastric adenocarcinoma [
         <a href="#rid53">
          53-56
         </a>
         ]. While SPEM may represent another separate pathway to gastric neoplasia, the two processes may be linked. Mouse models have shown that SPEM can develop following oxyntic atrophy through transdifferentiation of zymogen-secreting chief cells into cells that have a mucous secretory profile [
         <a href="#rid57">
          57
         </a>
         ]. Increasing evidence suggests that this process of chief cell reprogramming requires the influence of inflammatory cytokines in addition to oxyntic atrophy [
         <a href="#rid58">
          58
         </a>
         ], and that SPEM may represent a physiologic repair mechanism for recruiting reparative progenitor cells in response to mucosal wounds [
         <a href="#rid59">
          59
         </a>
         ]. More recent research has shown that the presence of SPEM allows
         <em>
          H. pylori
         </em>
         to access deeper regions along the gastric corpus unit, which may allow it to spread throughout the stomach [
         <a href="#rid60">
          60-62
         </a>
         ]. Evolution of intestinal metaplasia from SPEM may lead to a hyperproliferative state in which the infected and inflamed mucosa may be more susceptible to establishment of deleterious mutations in stem or progenitor cell populations [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1716006427">
         <span class="h4">
          Gastric dysplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric dysplasia, which represents a direct precursor of gastric adenocarcinoma, is a neoplastic lesion defined by cytologic and architectural features that are confined to the basement membrane (staged as Tis or carcinoma in situ according to the American Joint Committee on Cancer [AJCC] tumor, node, metastasis [TNM] staging criteria  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 1
         </a>
         )). It can present endoscopically as a flat, polypoid (ie, "adenoma"), or depressed lesion [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
         The prevalence of gastric dysplasia mirrors that of gastric adenocarcinoma, with regional variation [
         <a href="#rid65">
          65,66
         </a>
         ]. The mean age of patients is approximately a decade younger than that of those with gastric cancer, with a mean age of 61.35 versus 70 years [
         <a href="#rid67">
          67
         </a>
         ]. Male predominance is seen, similar to gastric cancer (male/female = 1.9/1) [
         <a href="#rid67">
          67,68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2586636538">
         <span class="h5">
          Etiology and pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk factors for gastric dysplasia are the same as those for gastric adenocarcinoma. It commonly develops in the background of chronic atrophic gastritis or intestinal metaplasia, and is strongly associated with
         <em>
          H. pylori
         </em>
         infection [
         <a href="#rid49">
          49,69-71
         </a>
         ].
        </p>
        <p>
         Although rare, dysplasia can also develop in nonadenomatous gastric polyps, even in the absence of
         <em>
          H. pylori
         </em>
         infection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with fundic gland polyps, the incidence of dysplasia is low, particularly in sporadic lesions (&lt;1 percent), while the incidence is reported to be up to 41 percent in fundic gland polyps that arise within the context of an inherited syndrome [
         <a href="#rid72">
          72-74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, even in the setting of familial adenomatous polyposis (FAP), progression from a polyp to an advanced lesion is uncommon, with only approximately 4 percent of cases developing high-grade dysplasia during follow-up [
         <a href="#rid75">
          75,76
         </a>
         ]. The incidence of
         <em>
          H. pylori
         </em>
         infection is very low in patients with fundic gland polyps. (See
         <a class="medical medical_review" href="/z/d/html/2518.html" rel="external">
          "Gastric polyps", section on 'Fundic gland polyps'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In hyperplastic polyps, which commonly develop in the setting of
         <em>
          H. pylori
         </em>
         infection or autoimmune gastritis, or secondary to bile reflux, the reported prevalence of dysplasia is low (&lt;2 percent), correlates with the size of the polyps, and is more common in lesions larger than &gt;2 cm [
         <a href="#rid77">
          77,78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2518.html" rel="external">
          "Gastric polyps", section on 'Hyperplastic polyps'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric dysplasia may also develop rarely in the setting of Peutz-Jeghers-related polyps and juvenile polyposis syndrome. (See
         <a class="medical medical_review" href="/z/d/html/15805.html" rel="external">
          "Juvenile polyposis syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2559572131">
         <span class="h5">
          Classification of dysplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to the World Health Organization (WHO), gastric epithelial dysplasia (also referred as glandular intraepithelial neoplasia) is classified into two grades: low- and high-grade dysplasia [
         <a href="#rid79">
          79
         </a>
         ]. Low-grade dysplastic lesions show minimal architectural disarray and are predominantly defined by cytologic features  (
         <a class="graphic graphic_picture graphicRef131612" href="/z/d/graphic/131612.html" rel="external">
          picture 5
         </a>
         ). The nuclei usually retain a basal orientation and present either no or limited loss of polarity. By contrast, high-grade dysplasia presents with more pronounced architectural disarray  (
         <a class="graphic graphic_picture graphicRef131613" href="/z/d/graphic/131613.html" rel="external">
          picture 6
         </a>
         ). Prominent cytologic atypia is also commonly detected, with cuboidal neoplastic cells, a high nucleus:cytoplasm ratio, clearing of the chromatin with prominent amphophilic nucleoli, and numerous mitoses, which can be atypical. The nuclei frequently extend into the luminal aspect of the cell, and nuclear polarity is usually lost. A third diagnostic category, indefinite for intraepithelial neoplasia, is reserved for cases for which a definitive diagnosis of dysplasia cannot be established with certainty. It may be used if the sampling submitted for evaluation is suboptimal or when a brisk inflammatory infiltrate may limit the morphologic evaluation.
        </p>
        <p>
         The nomenclature of advanced premalignant lesions in Japan has differed considerably from that of Western countries. In the West, invasive gastric cancer is typically defined by stromal invasion, while in Japan, severe nuclear and architectural abnormalities, even if confined to glandular structures, are considered sufficient to classify a lesion as "strongly suspicious for invasive carcinoma." Furthermore, Japanese pathologists use the term "borderline" to describe lesions that, in Western countries, would be labeled low-grade dysplasia [
         <a href="#rid80">
          80
         </a>
         ]. The Padova classification attempted to reconcile the two systems by assigning numerical categories based on the descriptive findings  (
         <a class="graphic graphic_table graphicRef58718" href="/z/d/graphic/58718.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid81">
          81
         </a>
         ]. A similar attempt was made in the Vienna Classification [
         <a href="#rid82">
          82
         </a>
         ]. The various classifications that have been proposed over the years are outlined in the table  (
         <a class="graphic graphic_table graphicRef120177" href="/z/d/graphic/120177.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         These discrepancies are more semantic than substantial. In Western countries, close endoscopic monitoring is considered appropriate for patients with low-grade gastric dysplasia, with intervention only if the lesions progress. On the other hand, the majority of clinicians (although not all) recommend surgical or endoscopic resection for patients with high-grade dysplasia [
         <a href="#rid83">
          83
         </a>
         ]. This is because areas of microinvasion can be found in some patients undergoing resection for high-grade dysplasia, although the proportion is not well established. In Japan, most "adenomas" and "early carcinomas" do not undergo surveillance but are treated with endoscopic resection, a technique that is used much less in the West. (See
         <a class="medical medical_review" href="/z/d/html/2520.html" rel="external">
          "Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4105589365">
         <span class="h5">
          Histopathologic subtypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of gastric epithelial dysplasia displays a histomorphology similar to colonic adenomas, including goblet and Paneth cells, and thus, it is sometimes qualified as adenomatous (or intestinal) dysplasia or type I dysplasia [
         <a href="#rid84">
          84-87
         </a>
         ].
        </p>
        <p>
         Type II dysplasia (gastric phenotype) is a second morphologic type of gastric dysplasia, composed of foveolar- or pyloric-type epithelium. Microscopically, the lesions are composed of low cuboidal cells with round to oval, nonstratified nuclei with a pale to clear cytoplasm (due to the presence of apical mucin caps, a feature of foveolar differentiation) or oncocytic to ground-glass cytoplasm (a feature of pyloric differentiation)  (
         <a class="graphic graphic_picture graphicRef131614 graphicRef131615 graphicRef131617" href="/z/d/graphic/131614.html" rel="external">
          picture 7A-C
         </a>
         ). The differentiation of nonadenomatous dysplasia can be confirmed immunohistochemically by expression of MUC5AC (a marker of foveolar differentiation) or MUC6 (a marker of pyloric differentiation) [
         <a href="#rid78">
          78
         </a>
         ]. Architectural characteristics of nonadenomatous dysplasia include glandular cystification and papillary and serrated architecture. While some investigators have found that type II dysplasia is more commonly associated with poorly differentiated (diffuse) gastric cancer, this is not universal, although a more aggressive biology of this subtype is suggested by others [
         <a href="#rid84">
          84,88-90
         </a>
         ].
        </p>
        <p>
         Some patients have dysplasia-like atypia that is limited to the pit epithelium but without involvement of the surface epithelium. The nature and significance of basal gland atypia/pit dysplasia, usually reported at the periphery of bona fide gastric dysplasia and as "indefinite for dysplasia" on a pathology report, remain to be confirmed. This lesion is characterized by an increased nuclear:cytoplasmic ratio, nuclear size and irregularity, hyperchromasia, and increased mitoses at the base of the pits with a normal mucosal surface [
         <a href="#rid91">
          91-94
         </a>
         ]. Most authors have concluded that this represents an important neoplastic precursor lesion in gastric carcinogenesis.
        </p>
        <p class="headingAnchor" id="H3623012680">
         <span class="h5">
          Progression of gastric dysplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rate of progression of gastric dysplasia is now believed to be much lower than previously thought, as shown in the following fairly contemporary population-based studies involving Western populations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 4331 Kaiser Permanente members who were diagnosed with gastric intestinal metaplasia or gastric dysplasia between 1997 and 2006 and followed through December 2016, 3.5 percent of patients with low-grade dysplasia and 59 percent of those with high-grade dysplasia developed an invasive adenocarcinoma within the first year; thereafter, only 4.3 percent of those with low-grade dysplasia progressed to invasive carcinoma [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a report of all patients with a first diagnosis of a premalignant gastric lesion between 1991 and 2004 who were identified in the Dutch nationwide histopathology registry, the annual incidence of gastric cancer was 0.6 percent for mild to moderate dysplasia and 6 percent for severe dysplasia within five years after diagnosis [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another series, 15.8 percent of patients with the initial histologic diagnosis "indefinite for dysplasia" developed a gastric cancer within 12 months, indicating that this diagnosis cannot be discounted [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In the context of an adenomatous gastric polyp, the probability of finding foci of invasive adenocarcinoma increases with an increase in the size of adenoma, and the risk is as high as 50 percent for polyps &gt;2 cm. Furthermore, a synchronous adenocarcinoma in another area of the stomach has been found in up to 30 percent of patients detected with an adenomatous gastric polyp [
         <a href="#rid86">
          86,96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H550119133">
         <span class="h2">
          Epstein-Barr virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with Epstein-Barr virus (EBV) is associated with a number of malignancies, especially nasopharyngeal carcinoma. (See
         <a class="medical medical_review" href="/z/d/html/3404.html" rel="external">
          "Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma", section on 'Epstein-Barr virus'
         </a>
         .)
        </p>
        <p>
         A possible role in gastric cancer was initially suggested in a study from Korea in which evidence of EBV was found in the tumor cells of 12 of 89 (13 percent) gastric carcinoma patients compared with none of 27 controls with a benign ulcer or any of the benign tissues from the cases [
         <a href="#rid97">
          97
         </a>
         ]. Some of the tumor cells had a histologic appearance similar to that of nasopharyngeal carcinoma. Since then, it has been estimated that between 5 and 10 percent of gastric cancers worldwide are associated with EBV [
         <a href="#rid98">
          98,99
         </a>
         ], although a role for EBV in gastric carcinogenesis, either directly or as a secondary effect, is debated [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
         EBV-associated gastric cancers (EBVaGCs) have distinct clinicopathologic characteristics, including male predominance, preferential location in the gastric cardia or postsurgical gastric stump, lymphocytic infiltration, a lower frequency of lymph node metastasis, perhaps a more favorable prognosis, and a diffuse type of histology in most [
         <a href="#rid101">
          101-105
         </a>
         ], but not all [
         <a href="#rid106">
          106-108
         </a>
         ], series. (See
         <a class="local">
          'Epstein-Barr virus-associated gastric cancer'
         </a>
         below.)
        </p>
        <p>
         In addition, in part due to the overexpression/amplification of programmed cell death ligand 1 (PD-L1) in EBVaGCs, these tumors are good candidates for therapy with immune checkpoint inhibitors. (See
         <a class="local">
          'Epstein-Barr virus-associated gastric cancer'
         </a>
         below and
         <a class="local">
          'PD-L1 overexpression and deficient mismatch repair'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2176922449">
         <span class="h2">
          Genetic predisposition and hereditary syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         First-degree relatives of patients with gastric cancer are almost three times as likely as the general population to develop gastric cancer [
         <a href="#rid109">
          109
         </a>
         ]. This may be partly attributable to
         <em>
          H. pylori
         </em>
         infection being common in families and to the potential role of inherited
         <em>
          IL-1
         </em>
         gene polymorphisms, which may affect the inflammatory response and gastric cancer risk associated with
         <em>
          H. pylori
         </em>
         infection [
         <a href="#rid21">
          21,22
         </a>
         ]. (See
         <a class="local">
          'Helicobacter pylori'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2617.html" rel="external">
          "Risk factors for gastric cancer", section on 'Familial predisposition'
         </a>
         .)
        </p>
        <p>
         However, while familial aggregation of gastric cancer occurs in around 10 to 20 percent of patients with gastric cancer, fewer than 5 percent of cases result from an inherited predisposition to cancer [
         <a href="#rid110">
          110-114
         </a>
         ]. One of these syndromes, hereditary diffuse gastric cancer (HDGC), is an autosomal dominant cancer susceptibility syndrome characterized by signet ring cell (diffuse) gastric cancer and lobular breast cancer; it is caused by a germline defect in the
         <em>
          CDH1
         </em>
         (E-cadherin 1) gene. (See
         <a class="local">
          'Hereditary diffuse gastric cancer'
         </a>
         below.)
        </p>
        <p>
         Two other types of familial predisposition to gastric cancer are described: familial intestinal gastric cancer (FIGC) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). The risk of developing gastric cancer is high in these families, but only HDGC is genetically explained. A summary of clinical features, recommendations for genetic screening, and the genetic alterations described for these three syndromes is outlined in the table  (
         <a class="graphic graphic_table graphicRef101357" href="/z/d/graphic/101357.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid110">
          110
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2617.html" rel="external">
          "Risk factors for gastric cancer", section on 'Familial predisposition'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1230423573">
         <span class="h3">
          Hereditary diffuse gastric cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         HDGC is an inherited form of diffuse-type gastric cancer, a highly invasive tumor that is characterized by late presentation and a poor prognosis. The lifetime risk of gastric cancer in individuals from these families is very high (cumulative risk of gastric cancer by age 80 years is reported to be 70 percent for males and 56 percent for females), and the median age at diagnosis is only 38 (although it ranges from 14 to 85 years of age). As a result, prophylactic total gastrectomy is usually advised, generally between ages 20 and 30. Almost all prophylactic gastrectomy specimens contain foci of early invasive gastric cancer. (See
         <a class="medical medical_review" href="/z/d/html/8041.html" rel="external">
          "Surgical management of hereditary diffuse gastric cancer", section on 'Timing of prophylactic total gastrectomy'
         </a>
         .)
        </p>
        <p>
         Affected individuals also have an increased risk for lobular breast cancer (cumulative risk by age 80 is approximately 42 percent). (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Breast cancer'
         </a>
         .)
        </p>
        <p>
         Many families with HDGC have germline pathogenic and likely pathogenic variants in the
         <em>
          CDH1
         </em>
         gene that are inherited in an autosomal dominant pattern. Germline
         <em>
          CDH1
         </em>
         pathogenic and likely pathogenic variants have been identified in approximately 15 to 50 percent of affected kindreds that meet the clinical criteria for HDGC, as defined by the International Gastric Cancer Linkage Consortium (IGCLC) [
         <a href="#rid115">
          115
         </a>
         ]. According to the two-hit hypothesis, a second-hit somatic event (commonly promoter hypermethylation) leading to biallelic inactivation is necessary for the development of gastric cancer in mutation carriers.
        </p>
        <p>
         Unlike the somatic mutations in
         <em>
          CDH1
         </em>
         that occur in sporadic gastric cancers and cluster around exons 7 and 8, the germline mutations in
         <em>
          CDH1
         </em>
         in HDGC families span the whole length of the gene, and no hot spots have been identified.
         <strong>
         </strong>
         Other potential candidate pathogenic variants have been identified in those who meet clinical criteria for HDGC but lack germline mutations in
         <em>
          CDH1
         </em>
         , including those in
         <em>
          CTNNA1
         </em>
         (the gene for alpha-catenin),
         <em>
          BRCA2
         </em>
         (the gene associated with hereditary breast and ovarian cancer syndrome),
         <em>
          STK11
         </em>
         (the gene associated with Peutz-Jeghers syndrome),
         <em>
          SDHB
         </em>
         ,
         <em>
          PRSS1
         </em>
         ,
         <em>
          ATM
         </em>
         ,
         <em>
          MSR1
         </em>
         , and
         <em>
          PALB2
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Molecular genetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1347751787">
         <span class="h3">
          Familial intestinal gastric cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         FIGC is characterized by an autosomal dominant pattern of inheritance of the intestinal subtype of gastric cancer in the absence of gastric polyposis. No specific genetic alterations have yet been linked to this syndrome. The incidence and specific risk for gastric cancer are not defined. Clinical criteria for diagnosis are outlined in the table  (
         <a class="graphic graphic_table graphicRef101357" href="/z/d/graphic/101357.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         The stomach cancers display the common macroscopic features observed in the sporadic setting of gastric cancer of the intestinal (gland-forming) type (see
         <a class="local">
          'Intestinal versus diffuse types'
         </a>
         below). Few recommendations are available for management of patients with suspected FIGC [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1222091721">
         <span class="h3">
          Gastric adenocarcinoma and proximal polyposis of the stomach
         </span>
         <span class="headingEndMark">
          —
         </span>
         GAPPS is an autosomal dominant cancer predisposition syndrome with a significant risk of gastric adenocarcinoma [
         <a href="#rid117">
          117
         </a>
         ]. Point mutations in promoter 1B of the adenomatous polyposis coli
         <em>
         </em>
         (
         <em>
          APC
         </em>
         ) gene cosegregated with disease in six GAPPS families [
         <a href="#rid118">
          118
         </a>
         ]. To date, few families with GAPPS are reported worldwide [
         <a href="#rid117">
          117-120
         </a>
         ]. The age of onset of gastric cancer is variable, and fundic gland polyposis with multifocal dysplasia has been detected as early as 10 years of age [
         <a href="#rid117">
          117,120
         </a>
         ]. The youngest patient who presented with generalized gastric adenocarcinoma presented at the age of 26 years [
         <a href="#rid120">
          120
         </a>
         ]. Scattered hyperplastic and pure adenomatous polyps and mixed polyps containing areas of dysplasia or gastric adenocarcinoma can be detected amid the fundic gastric polyps [
         <a href="#rid117">
          117
         </a>
         ]. Gastric cancers display the features of intestinal-type or mixed gastric cancer [
         <a href="#rid117">
          117,120
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H683949515">
         <span class="h3">
          Other inherited cancer syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric cancer has also been described in association with certain other inherited cancer syndromes, including Lynch syndrome (hereditary nonpolyposis colorectal cancer), FAP, Li-Fraumeni syndrome, Peutz-Jeghers syndrome, juvenile polyposis, hereditary breast and ovarian cancer syndrome, and, possibly, phosphatase and tensin homolog (PTEN) hamartoma tumor (Cowden) syndrome, but these are all fairly rare causes of gastric cancer. (See
         <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Extracolonic manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2593.html" rel="external">
          "Clinical manifestations and diagnosis of familial adenomatous polyposis", section on 'Extracolonic manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome", section on 'Spectrum of malignancies and age at onset'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Gastrointestinal cancers'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">
          "PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Gastric and duodenal polyps'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/758.html" rel="external">
          "Cancer risks and management of BRCA1/2 carriers without cancer", section on 'Other solid tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H265971062">
         <span class="h2">
          Other environmental factors implicated in the development of gastric cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other factors that play an important role in the causation of gastric cancer, particularly in conjunction with
         <em>
          H. pylori
         </em>
         infection, include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Smoking
         </strong>
         – Smoking tobacco increases the risk of gastric cancer, in part by potentiating the carcinogenic effect of infection with CagA-positive
         <em>
          H. pylori
         </em>
         [
         <a href="#rid121">
          121-124
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2617.html" rel="external">
          "Risk factors for gastric cancer", section on 'Smoking'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diet and nutrition
         </strong>
         – Diets high in salted, pickled, smoked, or poorly preserved foods; those with high meat content; and those with low fruit and vegetable content are most commonly associated with an increased risk for developing intestinal-type gastric cancer, particularly in combination with
         <em>
          H. pylori
         </em>
         infection [
         <a href="#rid125">
          125-131
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2617.html" rel="external">
          "Risk factors for gastric cancer", section on 'Diet'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bile reflux
         </strong>
         – Bile reflux has also been implicated. Patients with a gastric stump after previous gastric surgery have an increased risk of developing gastric cancer (reported frequencies range from 0.8 to 9 percent) [
         <a href="#rid132">
          132,133
         </a>
         ]. The risk appears to increase 15 to 25 years after the original surgery [
         <a href="#rid134">
          134-136
         </a>
         ]. Risk is higher following Billroth II gastrectomy and in those who have undergone surgery for a gastric ulcer, while those operated on for a duodenal ulcer are at a lower risk [
         <a href="#rid137">
          137
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2617.html" rel="external">
          "Risk factors for gastric cancer", section on 'Gastric surgery'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89634.html" rel="external">
          "Postgastrectomy complications", section on 'Remnant cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H766423870">
         <span class="h2">
          Autoimmune gastritis and gastric polyps
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune gastritis and pernicious anemia – Pernicious anemia is associated with an increased risk of gastric dysplasia and intestinal-type adenocarcinoma. However, the magnitude of the risk is debated; a two- to sixfold excess risk has been reported, but as with other predisposing conditions, the actual degree of risk varies with the duration of disease and geographic location. (See
         <a class="medical medical_review" href="/z/d/html/2617.html" rel="external">
          "Risk factors for gastric cancer", section on 'Pernicious anemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Finally, as noted above, gastric epithelial polyps, both neoplastic and nonneoplastic, can be associated with the development of gastric cancer; the key features are presented in the table  (
         <a class="graphic graphic_table graphicRef128990" href="/z/d/graphic/128990.html" rel="external">
          table 5
         </a>
         ). An exhaustive review of the preneoplastic nature of gastric polyps is beyond the scope of this review. Gastric epithelial polyps (hyperplastic polyps, adenomas) are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2518.html" rel="external">
          "Gastric polyps"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1361016697">
         <span class="h1">
          CLASSIFICATION OF GASTRIC CANCER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric cancers have been classified in a number of ways, including by anatomic location, disease extent, histomorphologic appearance, and molecular subtypes.
        </p>
        <p class="headingAnchor" id="H1427309621">
         <span class="h2">
          Anatomic classification and staging
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tumor, node, metastasis (TNM) staging systems of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) for esophagogastric junction cancers  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 6
         </a>
         ) and for gastric cancers  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 1
         </a>
         ) are used universally. In the most recent (2017, eighth edition) revision of the AJCC staging classification [
         <a href="#rid138">
          138
         </a>
         ], tumors involving the esophagogastric junction (EGJ) with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal cancers. By contrast, EGJ tumors with their epicenter located more than 2 cm into the proximal stomach are staged as stomach cancers, as are all cardia cancers not involving the EGJ, even if they are within 2 cm of the EGJ. (See
         <a class="medical medical_review" href="/z/d/html/2502.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of esophageal cancer", section on 'TNM staging criteria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2513.html" rel="external">
          "Clinical features, diagnosis, and staging of gastric cancer", section on 'TNM staging criteria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2046251877">
         <span class="h3">
          Patterns of disease spread and implications for staging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric carcinomas can spread either by direct extension to adjacent organs, metastasis, or peritoneal dissemination. Depending on the primary site within the stomach, penetration of the serosa may result in direct spread to the pancreas, liver, spleen, transverse colon, and/or greater omentum, and it often leads to early transperitoneal dissemination [
         <a href="#rid139">
          139
         </a>
         ]. Spread via the bloodstream occurs from invasion of tributaries of the portal vein, and the liver is the organ affected most commonly, followed by the lung and then the peritoneum. In general, gland-forming (ie, tubular, papillary, mucinous) carcinomas are more likely to give rise to liver metastases by hematogenous spread, while poorly cohesive carcinomas are more likely to involve the peritoneum than are gland-forming carcinomas. Peritoneal involvement is also more common in younger patients. (See
         <a class="local">
          'World Health Organization classification'
         </a>
         below.)
        </p>
        <p>
         World Health Organization (WHO) poorly cohesive (Lauren diffuse-type) cancers have a greater tendency to invade the gastric wall, sometimes extending to the lower esophagus or to the duodenum via submucosal or subserosal routes or via the submucosal lymphatics. Occasionally, a wide region of the gastric wall or even the entire stomach is extensively infiltrated, resulting in a rigid, thickened stomach, termed "linitis plastica"  (
         <a class="graphic graphic_diagnosticimage graphicRef79963" href="/z/d/graphic/79963.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef81537" href="/z/d/graphic/81537.html" rel="external">
          image 2
         </a>
         ). Bilateral massive ovarian involvement (Krukenberg tumor) can result from transperitoneal or hematogenous spread.
        </p>
        <p>
         Lymphatic and vascular invasion carries a poor prognosis in gastric cancer. The incidence of lymph node metastatic disease increases with the depth of tumor invasion [
         <a href="#rid140">
          140
         </a>
         ] and occurs with equal frequency regardless of histologic type. The distribution varies according to the location of the tumor  (
         <a class="graphic graphic_figure graphicRef111191" href="/z/d/graphic/111191.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2513.html" rel="external">
          "Clinical features, diagnosis, and staging of gastric cancer", section on 'Staging systems'
         </a>
         .)
        </p>
        <p>
         The accuracy of pathologic staging is proportional to the number of regional lymph nodes examined and their anatomic location in relation to the neoplasm. A discussion on the appropriate extent of lymph node dissection and the prognostic influence of primary tumor (T) and nodal (N) stage are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Extent of lymph node dissection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H663209009">
         <span class="h2">
          Early versus advanced
         </span>
        </p>
        <p class="headingAnchor" id="H1254856766">
         <span class="h3">
          Early gastric cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         The concept of early gastric cancer (EGC) originated in Japan in 1962; at that time, EGC was defined as a neoplasm that could be successfully treated with surgery. EGC is now defined more specifically as an adenocarcinoma that is restricted to the mucosa or submucosa  (
         <a class="graphic graphic_picture graphicRef131618" href="/z/d/graphic/131618.html" rel="external">
          picture 8
         </a>
         ), irrespective of lymph node metastasis (T1, any N)  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 1
         </a>
         ). These cancers have a significantly better prognosis (approximately 90 percent five-year survival rate) than do more advanced stages of gastric cancer. (See
         <a class="medical medical_review" href="/z/d/html/2520.html" rel="external">
          "Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging", section on 'Definition'
         </a>
         .)
        </p>
        <p>
         Importantly, this definition, which has been adopted by the Japanese National Cancer Centre, the Japan Gastric Cancer Association, and other international groups, acknowledges that there is a small percentage of patients with EGC who have lymph node involvement [
         <a href="#rid141">
          141
         </a>
         ]. These cancers should still be considered EGC, even if they have nodal metastases, as is supported by decades of investigation and data from screening programs [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         However, nodal metastases can affect treatment of EGC in two ways (see
         <a class="medical medical_review" href="/z/d/html/16858.html" rel="external">
          "Early gastric cancer: Treatment, natural history, and prognosis"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with biopsy-proven nodal metastases, patients whose pretreatment local staging evaluation indicates a high likelihood of nodal metastases, and patients with T1 disease who are at high risk for nodal metastases (because of tumor size, configuration, or depth of invasion) may not be appropriate candidates for endoscopic resection. Gastrectomy with removal of the regional nodes is the appropriate treatment strategy for such patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with node-positive resected EGC are candidates for adjuvant therapy.
        </p>
        <p>
        </p>
        <p>
         Countries with a high incidence of gastric cancer and in which asymptomatic patients are screened for gastric cancer have a high incidence of EGCs, ranging from 30 to 50 percent, with lower figures for Western populations (15 to 21 percent). (See
         <a class="medical medical_review" href="/z/d/html/2618.html" rel="external">
          "Gastric cancer screening"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2520.html" rel="external">
          "Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         EGCs are endoscopically divided into three types based on their appearance (the Paris system of classification  (
         <a class="graphic graphic_table graphicRef50239" href="/z/d/graphic/50239.html" rel="external">
          table 7
         </a>
         )). (See
         <a class="medical medical_review" href="/z/d/html/2520.html" rel="external">
          "Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging", section on 'Macroscopic classification'
         </a>
         .)
        </p>
        <p>
         Histologically, small (&lt;2 cm) and minute (&lt;5 mm) EGCs are commonly well differentiated. As tumor size increases and submucosal invasion develops, histologic diversity with mixed or poorly differentiated components is more common.
        </p>
        <p>
         EGCs are characterized by a low incidence of vessel invasion and lymph node metastasis, and a good prognosis (approximately 90 percent at 10 years). Endoscopic resection is an effective therapeutic choice for EGCs without clinical suspicion of lymph node metastasis that meets the following criteria:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High probability of en bloc resection
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor histology
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Differentiated adenocarcinoma
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumor confined to the mucosa
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of venous or lymphatic invasion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor size and morphology
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Less than 20 mm in diameter, without ulceration
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Less than 10 mm in diameter if Paris classification IIb or IIc  (
         <a class="graphic graphic_table graphicRef50239" href="/z/d/graphic/50239.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Gastrectomy is appropriate for patients with EGC who have lymph node involvement that is detected or highly suspected during the preoperative staging evaluation and for others who do not meet the standard criteria for endoscopic resection. Standard and expanded criteria for endoscopic resection of EGC are presented in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16858.html" rel="external">
          "Early gastric cancer: Treatment, natural history, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2003231829">
         <span class="h3">
          Advanced carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advanced gastric carcinomas can display various gross appearances. Bormann's classification divides gastric carcinomas into four distinct morphologic types: polypoid (type 1), fungating (type 2), ulcerated (type 3), and diffusely infiltrative (type 4)  (
         <a class="graphic graphic_figure graphicRef120444" href="/z/d/graphic/120444.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid142">
          142-145
         </a>
         ].
        </p>
        <p>
         Ulcerated tumors differ from benign ulcers by having an irregular margin with raised borders and thickened, uneven, and indurated surrounding mucosa. The ulcer base is necrotic, shaggy, and often nodular. Mucosal folds radiating from the crater are irregular and frequently show club-like thickening and fusion [
         <a href="#rid146">
          146
         </a>
         ]. Invasive adenocarcinoma, particularly when composed of poorly cohesive neoplastic cells, may spread superficially in the mucosa and submucosa, giving rise to plaque-like lesions with flattening of the rugal folds. In some cases, superficial ulceration supervenes. The infiltration may involve the entire thickness of the wall and produce the so-called linitis plastica appearance  (
         <a class="graphic graphic_diagnosticimage graphicRef79963" href="/z/d/graphic/79963.html" rel="external">
          image 1
         </a>
         ). Some mucinous adenocarcinomas may secrete considerable amounts of mucin, giving the tumor a gelatinous appearance.
        </p>
        <p class="headingAnchor" id="H28223660">
         <span class="h2">
          Histologic classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histologic classification of gastric adenocarcinoma is challenging because of intratumoral variations in architecture and/or differentiation, and several histologic classifications have been proposed over the years.
        </p>
        <p class="headingAnchor" id="H2301720967">
         <span class="h3">
          World Health Organization classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 2019 WHO classification, which does not take into account histogenesis and grade of differentiation, recognizes several main histologic types of malignant epithelial tumors (tubular, papillary, poorly cohesive signet ring phenotype, poorly cohesive other cell type, mucinous, mixed), as well as rare variants  (
         <a class="graphic graphic_table graphicRef129870" href="/z/d/graphic/129870.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3270102966">
         <span class="h3">
          Intestinal versus diffuse types
         </span>
         <span class="headingEndMark">
          —
         </span>
         The WHO classification does not include the morphologic "intestinal" and "diffuse" types of gastric cancer [
         <a href="#rid147">
          147
         </a>
         ]. At the cellular level, despite being classified as "intestinal," the neoplastic cells may show morphologic or immunophenotypical evidence not only of intestinal differentiation but also of gastric, gastrointestinal, unclassifiable, or null differentiation, underscoring the inadequacies of this histomorphologic classification.
        </p>
        <p>
         Nevertheless, since the seminal paper by Lauren in 1965, gastric adenocarcinomas have historically been divided into two distinct histomorphologic subtypes, intestinal (ie, gland-forming) and diffuse (composed of discohesive cells), which have a distinct morphologic appearance, epidemiology, pathogenesis, and genetic profile [
         <a href="#rid148">
          148-150
         </a>
         ]. Broadly, the morphologic differences are attributable to different genetic and epigenetic alterations, some related to intercellular adhesion molecules, which are preserved in intestinal-type tumors and defective in diffuse carcinomas:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In intestinal-type tumors, the tumor cells adhere to each other and tend to arrange themselves in tubular or glandular formations, similar to adenocarcinomas arising elsewhere in the intestinal tract (hence their designation as intestinal type)  (
         <a class="graphic graphic_picture graphicRef131619" href="/z/d/graphic/131619.html" rel="external">
          picture 9
         </a>
         ). The intestinal type is more common in males and older age groups, and they have a better prognosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, a lack of adhesion molecules in poorly cohesive carcinomas allows the individual tumor cells to grow and invade neighboring tissues without gland formation. Poorly cohesive carcinomas, including signet ring cell carcinomas, correspond to the diffuse type of the Lauren classification. They are composed of individual tumor cells invading the surrounding tissues and with no gland formation  (
         <a class="graphic graphic_picture graphicRef131620" href="/z/d/graphic/131620.html" rel="external">
          picture 10
         </a>
         ). This subtype can display various cell types that include neoplastic cells, such as signet ring cells, but also histiocytes as well as lymphocytes and others with a deeply eosinophilic cytoplasm. A mixture of these cell types including classical signet ring cells is commonly seen. These tumors show a more equal male:female ratio and are more frequent in younger individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It has long been considered that poorly cohesive histology is an independent predictor of a worse prognosis [
         <a href="#rid151">
          151,152
         </a>
         ]. However, more recent studies have begun to question this notion, with the suggestion that signet ring histology is associated with a more advanced stage of disease and that, when adjusted for stage, poorly cohesive tumors do not portend a worse prognosis [
         <a href="#rid153">
          153-158
         </a>
         ]. In a large-scale study, it was shown that early stage signet ring cell/diffuse carcinomas can be indolent, and more than one-half of the cases are presented as EGC [
         <a href="#rid159">
          159
         </a>
         ]. On the other hand, signet ring cell/diffuse carcinomas in advanced stages bestow a worse prognosis than well or moderately differentiated carcinomas.
        </p>
        <p>
        </p>
        <p>
         A molecular basis for this difference is now apparent. The main carcinogenic event in diffuse carcinomas is loss of expression of E-cadherin, a key cell surface protein for establishing intercellular connections and maintaining the organization of epithelial tissues [
         <a href="#rid160">
          160
         </a>
         ]. Loss of expression of E-cadherin leads to defective intercellular adhesions. Biallelic inactivation of the gene encoding E-cadherin (
         <em>
          CDH1
         </em>
         ) can occur through germline or somatic mutation, allelic imbalance events (eg, loss of heterozygosity), or epigenetic silencing of gene transcription through aberrant methylation of the CDH1 promoter. Individuals who inherit germline
         <em>
          CDH1
         </em>
         mutations are considered to have hereditary diffuse gastric cancer (HDGC), and they are predisposed both to EGC  (
         <a class="graphic graphic_picture graphicRef131621" href="/z/d/graphic/131621.html" rel="external">
          picture 11
         </a>
         ) and lobular breast cancer. (See
         <a class="local">
          'Hereditary diffuse gastric cancer'
         </a>
         above.)
        </p>
        <p>
         In direct contrast, the molecular basis underlying intestinal-type gastric cancers is less well defined. However, it appears to follow a multistep progression that is usually initiated by
         <em>
          H. pylori
         </em>
         infection. Like intestinal-type cancers, diffuse-type gastric carcinomas also can be induced by
         <em>
          H. pylori
         </em>
         infection. However, in contrast with intestinal-type cancers, a defined series of preneoplastic stages is not well defined. (See
         <a class="local">
          'Helicobacter pylori'
         </a>
         above.)
        </p>
        <p>
         Early stage HDGC in
         <em>
          CDH1
         </em>
         mutation carriers is characterized by multiple foci
         <em>
         </em>
         of invasive (T1a) signet ring cell (diffuse, poorly cohesive) carcinoma in the superficial gastric mucosa without nodal metastases [
         <a href="#rid161">
          161-164
         </a>
         ]. Precursor lesions (Tis) can be recognized: pagetoid spread of signet ring cells below the preserved epithelium of glands and foveolae but within the basal membrane, or in situ signet ring cell carcinoma, corresponding to the presence of signet ring cells within the basal membrane, substituting the normal epithelial cells [
         <a href="#rid27">
          27
         </a>
         ]. In these lesions, E-cadherin immunoexpression is reduced or absent [
         <a href="#rid27">
          27,163,165,166
         </a>
         ]. Because the EGCs that develop in these individuals are multifocal and located beneath an intact mucosal surface [
         <a href="#rid161">
          161
         </a>
         ], early detection is difficult. Given this fact, and the poor prognosis of these tumors when locoregionally advanced, patients with evidence of a
         <em>
          CDH1
         </em>
         germline mutation in the context of a family history of HDGC are candidates for prophylactic gastrectomy. (See
         <a class="medical medical_review" href="/z/d/html/8041.html" rel="external">
          "Surgical management of hereditary diffuse gastric cancer", section on 'Indications for prophylactic total gastrectomy'
         </a>
         .)
        </p>
        <p>
         Abnormalities in
         <em>
          CDH1
         </em>
         have also been linked to sporadic diffuse (and intestinal) carcinomas. Somatic mutations in the
         <em>
          CDH1
         </em>
         gene are identified in 40 to 83 percent of sporadic diffuse-type gastric cancers [
         <a href="#rid167">
          167-170
         </a>
         ]. One analysis of 174 sporadic gastric cancers found that
         <em>
          CDH1
         </em>
         alterations (both structural alterations, such as mutations or loss of heterozygosity, and epigenetic alterations) were present in 34 percent of diffuse-type gastric cancers and in 26 percent of intestinal cancers [
         <a href="#rid171">
          171
         </a>
         ]. This analysis found no structural alterations among 19 patients with HDGC, but 53 percent harbored an epigenetic methylation.
        </p>
        <p class="headingAnchor" id="H2747605296">
         <span class="h3">
          Special-type gastric cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several subtypes with characteristic morphology are also recognized in the WHO classification, emphasizing the diversity of the disease  (
         <a class="graphic graphic_table graphicRef129870" href="/z/d/graphic/129870.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid147">
          147
         </a>
         ]. Some are related to either specific etiopathogenic or molecular alterations.
        </p>
        <p class="headingAnchor" id="H575324073">
         <span class="h4">
          Epstein-Barr virus-associated gastric cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric carcinoma with lymphoid stroma [
         <a href="#rid147">
          147,172
         </a>
         ] or lymphoepithelioma-like carcinoma are associated with Epstein-Barr virus (EBV) infection and are designated as EBV-associated gastric cancers (EBVaGCs)  (
         <a class="graphic graphic_picture graphicRef131622" href="/z/d/graphic/131622.html" rel="external">
          picture 12
         </a>
         ) [
         <a href="#rid173">
          173-175
         </a>
         ]. A similar morphology can be observed in gastric cancers with microsatellite instability [
         <a href="#rid176">
          176,177
         </a>
         ]. Overall, the frequency of finding evidence of EBV infection in gastric carcinomas ranges from 2 to 20 percent, with a worldwide average of nearly 10 percent [
         <a href="#rid100">
          100,178,179
         </a>
         ]. However, as noted above, a role for EBV in gastric carcinogenesis, either directly or as a secondary effect, is debated. (See
         <a class="local">
          'Epstein-Barr virus'
         </a>
         above.)
        </p>
        <p>
         EBVaGCs display certain distinctive macroscopic and histologic characteristics [
         <a href="#rid172">
          172,175,180
         </a>
         ]. Gastric carcinoma with lymphoid stroma is the main variant, and it occurs predominantly in the proximal stomach [
         <a href="#rid105">
          105,181
         </a>
         ] and in the gastric stump of patients with a previous partial gastrectomy [
         <a href="#rid182">
          182
         </a>
         ]. The patients are younger than in conventional carcinoma, and males are affected more often [
         <a href="#rid105">
          105,172,173,180
         </a>
         ]. The tumors usually have a well-demarcated pushing, rather than infiltrating, margin. They are typically composed of irregular sheets; trabeculae; ill-defined tubules of polygonal cells admixed with a prominent lymphocytic infiltrate composed of CD8-positive cytotoxic T lymphocytes and, to a lesser degree, B lymphocytes; plasma cells; neutrophils; and eosinophils. Notably, most, but not all, gastric cancers with lymphoid stroma appear to be EBV related  (
         <a class="graphic graphic_picture graphicRef131622" href="/z/d/graphic/131622.html" rel="external">
          picture 12
         </a>
         ) [
         <a href="#rid173">
          173
         </a>
         ].
        </p>
        <p>
         Two other variants of EBVaGCs are observed: tubular carcinomas with limited desmoplasia, a smaller number of lymphocytes, and prominent lymphoid follicles with active germinal centers (designated as "carcinoma with Crohn disease-like lymphoid reaction") and conventional-type adenocarcinomas with scant lymphocytic infiltrate [
         <a href="#rid181">
          181
         </a>
         ]. The prognosis is reportedly better than that for typical gastric cancers [
         <a href="#rid101">
          101,102,105-107,173-175,180,182-186
         </a>
         ].
        </p>
        <p>
         In part due to the overexpression/amplification of programmed cell death ligand 1 (PD-L1) in gastric cancers associated with EBV, these tumors are good candidates for therapy with immune checkpoint inhibitors [
         <a href="#rid187">
          187-190
         </a>
         ]. (See
         <a class="local">
          'The Cancer Genome Atlas'
         </a>
         below and
         <a class="local">
          'PD-L1 overexpression and deficient mismatch repair'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'Immunotherapy-based regimens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121739.html" rel="external">
          "Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'Biomarkers and benefit from PD-1 inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H797340006">
         <span class="h4">
          Adenosquamous and squamous cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         In adenosquamous carcinoma, the neoplastic squamous component comprises at least 25 percent of the tumor volume, characterized by keratin pearl formation and intercellular bridges in addition to the glandular element [
         <a href="#rid191">
          191
         </a>
         ]. Metastases usually contain both glandular and squamous components, but in some instances, only one component may be present [
         <a href="#rid192">
          192
         </a>
         ].
        </p>
        <p>
         Pure squamous cell carcinomas of the stomach [
         <a href="#rid193">
          193-195
         </a>
         ] are usually diagnosed at a late stage and have a poor prognosis [
         <a href="#rid195">
          195
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3506227227">
         <span class="h4">
          Micropapillary carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Micropapillary carcinoma (MPC) is an uncommon subtype of gastric cancer (incidence approximately 6 percent) that is characterized by irregular, small, mole-like clusters of tumor cells lying within clear lacunar spaces that simulate lymphatic or vascular channels. Most cases are associated with classic tubular or papillary adenocarcinomas. The proportion of the MPC component ranges from 5 to 80 percent [
         <a href="#rid196">
          196
         </a>
         ]. MPC carcinoma is an aggressive subtype, with a high incidence of nodal metastasis at diagnosis [
         <a href="#rid197">
          197-199
         </a>
         ] and worse survival rates than for those with non-MPC gastric carcinomas [
         <a href="#rid196">
          196,197
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1505634413">
         <span class="h4">
          Gastric adenocarcinoma of fundic gland type
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric adenocarcinoma of fundic gland type (chief cell predominant type) [
         <a href="#rid200">
          200
         </a>
         ] is a rare variant of gastric cancer. Despite the presence of minimal invasion into the submucosal layer, lymphatic or venous invasion is extremely rare [
         <a href="#rid201">
          201,202
         </a>
         ]. The characteristic microscopic appearance is an irregularly anastomosing glandular pattern lined by chief cells and a variable number of parietal cells with mildly enlarged and hyperchromatic nuclei  (
         <a class="graphic graphic_picture graphicRef131623" href="/z/d/graphic/131623.html" rel="external">
          picture 13
         </a>
         ). The neoplastic chief cells express MUC6 and pepsinogen-I (gastric phenotype).
        </p>
        <p>
         The best terminology has been debated, with some supporting the term "oxyntic gland polyp/adenoma" as more appropriate for this type of lesion [
         <a href="#rid203">
          203,204
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2305487820">
         <span class="h2">
          Molecular subtyping
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advances in high-throughput genomic technologies have led to rapid advances in the understanding of the genomic, epigenomic, transcriptomic, and proteomic changes that underlie gastric cancer pathobiology. Gastric cancers have a high frequency of somatic mutations as well as substantial interindividual variability of mutational load. One study, based on next-generation sequencing (NGS)-based estimates, reported that each case of gastric cancer (with the exception of hypermutated cases) presents 50 to 70 nonsynonymous mutations [
         <a href="#rid205">
          205
         </a>
         ]. The frequency of somatic mutations of genes noted in gastric cancer has allowed a three-tiered classification: genes with a high frequency rate of mutations (&gt;5 to 10 percent) across non-multiple gastric cancers, genes with a low frequency rate (recurrently mutated in the 1 to 10 percent range), and bystander/passenger mutations that arise secondary to underlying mutational processes but do not contribute to gastric carcinogenesis. For example,
         <em>
          TP53
         </em>
         is the most commonly mutated gene in gastric cancer, with mutations detected in approximately 50 percent of the cases [
         <a href="#rid189">
          189,206-208
         </a>
         ].
        </p>
        <p>
         Various studies have sought to incorporate multiple molecular readouts to delineate the mechanisms of disease biology and discern potentially useful therapeutic molecular targets. As an example, The Cancer Genome Atlas (TCGA) performed a comprehensive analysis of multiple "omic" (copy number, mutational, DNA methylation, transcriptome, and proteome) readouts with 295 gastric adenocarcinomas profiled on all five platforms [
         <a href="#rid189">
          189
         </a>
         ]. Others, the Asian Cancer Research Group (ACRG), have analyzed 251 gastric cancers through a combination of gene expression profiling, genome-wide copy marker microarrays, and targeted gene sequencing, generating gene expression profiles by comparing their results to a predefined set of gene expression signatures: epithelial to mesenchymal transition (EMT), microsatellite instability, cytokine signaling, cell proliferation, and DNA methylation [
         <a href="#rid208">
          208
         </a>
         ]. Another study led by the Duke-National University of Singapore compared the gene expression patterns among 248 gastric adenocarcinomas using consensus hierarchical clustering with iterative feature selection [
         <a href="#rid209">
          209
         </a>
         ]. Collectively, these studies report a diverse spectrum of mutational frequencies, with dominant subclones centered around a handful of driver mutations that can form the basis for a molecular classification of gastric cancer.
        </p>
        <p>
         The three studies described above emphasize that gastric cancer is not a single entity but a complex and heterogeneous group of diseases with distinct biologic and clinical features. A premise of precision medicine is that the appropriate matching of tumor molecular subtypes with targeted therapeutic agents will offer superior efficacy and less toxicity, thereby improving clinical outcomes. On a practical level, robust molecular gastric cancer subtyping may resolve, to some degree, the heterogeneity of existing classification schemes, whether surgical, endoscopic, or histopathologic, which remain insufficient to guide treatment for individual patients. These novel attempts at classifying gastric adenocarcinomas integrate the genomic and transcriptomic profiles to define integrative clusters characterized by distinct clinical and morphologic characteristics as well as prognostic outcomes. Ultimately these findings are expected to have significant implications for patient stratification and tailored therapeutic approaches.
        </p>
        <p class="headingAnchor" id="H3816812104">
         <span class="h3">
          The Cancer Genome Atlas
         </span>
         <span class="headingEndMark">
          —
         </span>
         TCGA confirmed a high frequency (&gt;10 percent overall) of somatic mutations in a handful of genes (
         <em>
          TP53
         </em>
         ,
         <em>
          PIK3CA
         </em>
         , and
         <em>
          ARID1A
         </em>
         [AT-rich interaction domain-containing protein 1A]) [
         <a href="#rid189">
          189
         </a>
         ]. A second group of genes (
         <em>
          SMAD4
         </em>
         ,
         <em>
          RhoA
         </em>
         [RAS homolog gene family, member A],
         <em>
          KRAS
         </em>
         , and
         <em>
          APC
         </em>
         [adenomatous polyposis coli]) were mutated in 6 to 8 percent of the cases, whereas the vast majority of mutations were discovered in a small (1 to 3 percent) proportion of cases. Based on molecular features, these investigators identified four major molecular subtypes of gastric cancer, which are summarized in the table  (
         <a class="graphic graphic_table graphicRef128991" href="/z/d/graphic/128991.html" rel="external">
          table 9
         </a>
         ), and described in more detail in the sections below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetically stable gastric cancers
         </strong>
         – These cases represent approximately 20 percent of gastric cancers. These tumors are usually aneuploid and diagnosed at an earlier age [
         <a href="#rid142">
          142
         </a>
         ]. There is an enrichment of the diffuse subtype in this group (73 percent), and they tend to present at a distal location within the stomach. In this subgroup,
         <em>
          CDH1
         </em>
         somatic mutations are present in 37 percent of the cases, but extensive copy number aberrations are rare. Inactivating mutations of
         <em>
          ARID1A
         </em>
         are noted within this subset, and mutations of the
         <em>
          RhoA
         </em>
         gene were extensively noted in this group as well. This finding is not unexpected since most of these tumors have a poorly cohesive phenotype, and there is a demonstrated role of
         <em>
          RhoA
         </em>
         in diffuse gastric cancer cellular motility [
         <a href="#rid210">
          210
         </a>
         ]. A subset of these tumors also showed a translocation between claudin 18 and the RHO GTPase activating protein 26 genes (the
         <em>
          CLDN18
         </em>
         -
         <em>
          ARHGAP26
         </em>
         fusion gene), an alteration also likely to contribute to the diffuse phenotype since it is enriched in younger-onset-age gastric cancers [
         <a href="#rid211">
          211
         </a>
         ], it is associated with loss of epithelial integrity [
         <a href="#rid212">
          212
         </a>
         ], and claudin proteins are a component of the tight junction adherens structure [
         <a href="#rid213">
          213
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chromosomally unstable gastric cancers
         </strong>
         – These neoplasms represent approximately 50 percent of gastric cancers, and the frequency of this subtype is increased in EGJ cancers. Chromosomal instability is characterized by DNA aneuploidy, structural changes of chromosomes (eg, translocations), and mutations in various proto-oncogenes and tumor suppressor genes. These cancers mostly exhibit an intestinal morphology, a high number of
         <em>
          TP53
         </em>
         mutations (70 percent), as reflected histologically by
         <em>
          P53
         </em>
         overexpression  (
         <a class="graphic graphic_picture graphicRef131624" href="/z/d/graphic/131624.html" rel="external">
          picture 14
         </a>
         ), and amplifications of tyrosine kinase receptors. Phosphorylation of the epidermal growth factor receptor (EGFR) is significantly elevated in this group, while aneuploidy is also frequent. These lesions with frequent
         <em>
          TP53
         </em>
         mutations fall into the proliferation subtype of the Duke-National University of Singapore [
         <a href="#rid209">
          209
         </a>
         ]. Other genes frequently amplified within this molecularly defined subgroup include
         <em>
          CCNE1
         </em>
         ,
         <em>
          MYC
         </em>
         ,
         <em>
          ERBB2
         </em>
         (
         <em>
          HER2
         </em>
         ), and
         <em>
          KRAS
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Human epidermal growth factor receptor 2 (HER2), which is a member of the EGFR family of proteins, is a transmembrane tyrosine kinase receptor that regulates cell proliferation, differentiation, and survival [
         <a href="#rid214">
          214
         </a>
         ]. Approximately 10 to 20 percent of gastric adenocarcinomas are HER2 positive, and overexpression of this protein indicates the potential for responsiveness to HER2-targeted treatments (ie,
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         ). (See
         <a class="local">
          'HER2 overexpression'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microsatellite unstable (mismatch repair deficient) gastric cancers
         </strong>
         – Microsatellite instability is the biologic footprint of deficiency in DNA mismatch repair (dMMR). Microsatellite unstable gastric cancers represent approximately 22 percent of gastric cancer cases and are characterized by a high mutation rate (with an average of 50 mutations per neoplasm, compared with approximately ≤5 in the other subtypes). In microsatellite unstable sporadic gastric cancers, the mismatch repair defect is most frequently caused by an epigenetic event (hypermethylation in the MLH1 promoter region) [
         <a href="#rid215">
          215
         </a>
         ]. In rare cases, a germline mutation in a mismatch repair gene is inherited and causes Lynch syndrome, which most often leads to colorectal and endometrial cancers, but gastric cancers also arise in up to 10 percent of such families [
         <a href="#rid216">
          216
         </a>
         ]. Microsatellite unstable (dMMR) gastric cancers can be identified immunohistochemically by loss of expression of one of the DNA mismatch repair genes  (
         <a class="graphic graphic_picture graphicRef131625" href="/z/d/graphic/131625.html" rel="external">
          picture 15
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypermutations are frequent in the
         <em>
          KRAS
         </em>
         , anaplastic lymphoma kinase (
         <em>
          ALK
         </em>
         ),
         <em>
          ARID1A
         </em>
         , and
         <em>
          PI3K
         </em>
         -
         <em>
          PTEN
         </em>
         mechanistic (previously called mammalian) target of rapamycin (mTOR) pathway. These lesions occur at a relatively older age and tend to affect females disproportionately [
         <a href="#rid142">
          142
         </a>
         ]. Most arise in the antrum, have an intestinal phenotype, and are more likely to be diagnosed at an earlier stage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         dMMR also identifies tumors that may respond to immune checkpoint inhibitor immunotherapy. (See
         <a class="local">
          'PD-L1 overexpression and deficient mismatch repair'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastric cancers with Epstein-Barr virus infection
         </strong>
         – These tumors constitute approximately 9 percent of gastric cancers and tend to affect males preferentially. These lesions are frequently located in the fundus and body have a lower frequency of lymph node metastases, and have a lower mortality rate. EBV-positive tumors show an extreme CpG island methylator phenotype. Characteristics of these tumors include
         <em>
          CDKN2A
         </em>
         promoter hypermethylation and nonsilent mutation of
         <em>
          PIK3CA
         </em>
         (in 80 percent of the cases). Other frequently mutated genes include
         <em>
          ARID1A
         </em>
         , which encodes for an antiapoptotic protein [
         <a href="#rid142">
          142
         </a>
         ].
         <em>
          JAK2
         </em>
         and
         <em>
          ERBB2
         </em>
         (
         <em>
          HER2
         </em>
         ) amplifications are also common.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This subgroup also shows, in approximately 10 percent of the cases, recurrent 9p24.1 amplification at the locus containing
         <em>
          JAK2
         </em>
         ,
         <em>
          CD274
         </em>
         , and
         <em>
          PDCD1LG2
         </em>
         , which is significant since
         <em>
          CD274
         </em>
         and
         <em>
          PDCD1LG2
         </em>
         encode PD-L1 and programmed cell death ligand 2 (PD-L2). These two proteins help the neoplastic cells to escape from the body's antitumoral immune response, by binding to programmed cell death receptor 1 (PD-1), which is expressed on cytotoxic T cells. These molecules are of particular relevance as targets for immune checkpoint inhibitor immunotherapy. (See
         <a class="local">
          'PD-L1 overexpression and deficient mismatch repair'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         From a prognostic standpoint, the EBV-related subtype is associated with the best prognosis, and the genetically stable subtype is associated with the worst survival  (
         <a class="graphic graphic_figure graphicRef120447" href="/z/d/graphic/120447.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid217">
          217
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3655547547">
         <span class="h3">
          Asian Cancer Research Group
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ACRG also identified four molecularly defined subgroups [
         <a href="#rid208">
          208
         </a>
         ], which differ from those identified by TCGA, although there is at least some overlap:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A mesenchymal group microsatellite stable (MSS)/EMT (15.3 percent of cases) based on the evidence of EMT; this subtype occurred mainly at an advanced stage, at a younger age, and with a diffuse histology (&gt;80 percent), including a large set of signet ring cell carcinomas seeding in the peritoneum with malignant ascites (64 versus 15 to 24 percent of the other subtypes), and it showed loss of CDHG1 expression. This subtype had the worst prognosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An MSS/
         <em>
          TP53
         </em>
         -negative subtype (35.7 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An MSS/
         <em>
          TP53
         </em>
         -positive subtype (26.3 percent); EBV infection was more frequent in this subgroup.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A microsatellite unstable subtype (22.7 percent); this occurs predominantly at an early stage in the distal part of the stomach and showed mainly intestinal histology.
        </p>
        <p>
        </p>
        <p>
         Overall, the microsatellite unstable subtype has the best prognosis, while the MSS/EMT subtype has the worst  (
         <a class="graphic graphic_figure graphicRef120446" href="/z/d/graphic/120446.html" rel="external">
          figure 5
         </a>
         ).
        </p>
        <p>
         A comparison of the key characteristics of both the ACRG and TCGA molecular classifications is provided in the table  (
         <a class="graphic graphic_table graphicRef120399" href="/z/d/graphic/120399.html" rel="external">
          table 10
         </a>
         ) [
         <a href="#rid218">
          218
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3669577588">
         <span class="h3">
          Clinical implications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the molecular characterization of gastric cancers as described above has identified gene signatures that are prognostically relevant, they are still inadequate to direct molecularly targeted therapy, with few exceptions.
        </p>
        <p>
         Currently, there are only three therapeutically relevant, routinely tested molecular biomarkers in gastric carcinoma: overexpression of HER2 (ERBB2), which permits the selection of patients with advanced disease who might benefit from
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , and overexpression of PD-L1/dMMR, both of which identify patients with advanced disease with the potential to benefit from immune checkpoint inhibitor immunotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'Cytotoxic chemotherapy options'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121739.html" rel="external">
          "Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'Biomarkers and benefit from PD-1 inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H335357425">
         <span class="h4">
          HER2 overexpression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 10 to 20 percent of gastric adenocarcinomas have human epidermal growth factor receptor 2 (
         <em>
          HER2
         </em>
         ) gene amplification, which results in overexpression of HER2, a receptor tyrosine kinase and member of the EGFR family  (
         <a class="graphic graphic_picture graphicRef131626" href="/z/d/graphic/131626.html" rel="external">
          picture 16
         </a>
         ). Overexpression of
         <em>
          HER2
         </em>
         is most frequent in the TCGA-defined chromosomally unstable subset of gastric cancers. ACRG data documented that
         <em>
          HER2
         </em>
         gene amplifications are enriched in the MSS/
         <em>
          TP53-
         </em>
         negative subtype (present in 17 percent of cases) [
         <a href="#rid208">
          208
         </a>
         ].
         <em>
         </em>
         In general,
         <em>
          HER2
         </em>
         amplifications are more common in adenocarcinomas of the gastroesophageal junction (GEJ) compared with gastric adenocarcinomas, in the Lauren intestinal subtype compared with the diffuse subtype, and in well and moderately differentiated tumors compared with poorly differentiated tumors [
         <a href="#rid219">
          219
         </a>
         ]. Others note that the
         <em>
          HER2
         </em>
         amplification rate depends on ethnicity and geography [
         <a href="#rid220">
          220
         </a>
         ]. Other
         <em>
          HER2
         </em>
         abnormalities, such as mutations, are also known to occur; however, interactions between mutations and protein expression have not been studied extensively compared with amplifications.
        </p>
        <p>
         HER2 overexpression identifies patients with advanced disease who might benefit from the addition of
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         to a cytotoxic chemotherapy backbone. Trastuzumab is a recombinant humanized monoclonal antibody that targets the extracellular domain IV of HER2 and acts against overexpressed HER2 protein on the cell membrane, blocking the downstream effects [
         <a href="#rid221">
          221
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'HER2-overexpressing adenocarcinomas'
         </a>
         .)
        </p>
        <p>
         Accurate determination of HER2 status is important, using a rigorous testing algorithm and robust definitions of gene amplification and protein overexpression to predict those patients who will most benefit from
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         . In comparison with breast carcinomas, the heterogeneity of immunostaining for HER2 protein overexpression is greater in gastroesophageal adenocarcinomas, and the possibility of false-negative testing is higher [
         <a href="#rid222">
          222,223
         </a>
         ]. Furthermore, HER2 protein expression in gastroesophageal adenocarcinomas tends to spare the digestive luminal membrane, resulting in membrane staining that is not completely circumferential in contrast to breast cancers [
         <a href="#rid224">
          224-226
         </a>
         ]. These differences underscore the importance of utilizing tumor-specific criteria to assess HER2 expression in clinical practice. Most robust testing algorithms combine IHC and ISH techniques to assess HER2 status. In general, bright-field silver in situ hybridization (SISH) is superior to the dark-field ISH (eg, fluorescence in situ hybridization [FISH]) [
         <a href="#rid227">
          227,228
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer"
         </a>
         .)
        </p>
        <p>
         Concordance of HER2 status between biopsy and resection specimens, as well as primary and metastatic sites, is very high but not perfect [
         <a href="#rid229">
          229
         </a>
         ]. Heterogeneous amplification of
         <em>
          HER2
         </em>
         in primary lesions is thought to be responsible for most of the discordant HER2 statuses of primary and metastatic lesions in gastric carcinoma [
         <a href="#rid229">
          229,230
         </a>
         ]. However, concordance rates as high as 95 to 98 percent have been reported in paired samples [
         <a href="#rid231">
          231
         </a>
         ].
        </p>
        <p>
         Nevertheless, insufficient tumor representation in endoscopic biopsies may lead to a false-negative result. Analyzing HER2 positivity in &lt;6 biopsy samples leads to a false-negative rate that may be as high as 9 percent [
         <a href="#rid229">
          229,232-237
         </a>
         ]. The optimal number of tumor fragments that is required for testing of endoscopic biopsies is at least five [
         <a href="#rid238">
          238,239
         </a>
         ].
        </p>
        <p>
         Given the differences in interpretive criteria for determining HER2 status in gastroesophageal as compared with breast cancers [
         <a href="#rid224">
          224,225,240-242
         </a>
         ], an expert panel convened by the College of American Pathologists (CAP), American Society of Clinical Pathology (ASCP), and American Society of Clinical Oncology (ASCO) undertook a systematic review of the published literature to provide an evidence-based joint guideline on HER2 testing and clinical decision making in gastroesophageal adenocarcinomas [
         <a href="#rid222">
          222
         </a>
         ]. Among the panel's recommendations were the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For biopsy or resection specimens, a minimum of five specimens, optimally six to eight, should be tested to account for intratumoral heterogeneity (when possible). If there is documentation of HER2 positivity on any specimen, the treating clinician does not need to request additional HER2 testing on additional specimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HER2 testing on fine needle aspirate specimens is an acceptable alternative. However, specimens obtained in cytology specimens may not be truly representative given the limited sampling of the tumor. If there is concern about specimen adequacy and HER2 testing is negative, additional available primary or metastatic tumor tissue should be tested.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When HER2 status is being evaluated, laboratories/pathologists should perform/order IHC staining first. Pathologists should use the Ruschoff/Hoffmann method in scoring IHC results  (
         <a class="graphic graphic_table graphicRef110996" href="/z/d/graphic/110996.html" rel="external">
          table 11
         </a>
         ) and should select the tissue block with the areas of lowest grade or intestinal morphology for testing. A positive result is IHC 3+. A negative result is IHC 0 to 1+ [
         <a href="#rid222">
          222
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FISH or another ISH method is recommended only when the IHC result is 2+ (equivocal) to determine amplification status. In many studies, ISH-positive results are observed in 30 to 50 percent of IHC 2+ tumors. A variety of in situ visualization techniques to evaluate HER2 amplification, including FISH and brightfield ISH using either a HER2 probe or dual HER2 and centromere (chromosome enumeration probe 17 [CEP17]) probes, are all acceptable strategies. A ratio of HER2 signal to CEP17 signal ≥2 is considered positive, while a HER2:CEP17 ratio &lt;2.0 is considered negative. An algorithmic approach to assessing HER2 status on surgical and biopsy material is presented in the figure  (
         <a class="graphic graphic_algorithm graphicRef110995" href="/z/d/graphic/110995.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         The initial management of patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'HER2-overexpressing adenocarcinomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3631569018">
         <span class="h4">
          PD-L1 overexpression and deficient mismatch repair
         </span>
         <span class="headingEndMark">
          —
         </span>
         The programmed cell death receptor 1 (PD-1) is a key immune checkpoint receptor that is expressed by activated T cells [
         <a href="#rid243">
          243,244
         </a>
         ]. Tumors use the PD-1 pathway to evade immune surveillance. PD-1 binds to its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC), which are overexpressed on tumor cells, thereby preventing the immune system from rejecting the tumor. (See
         <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">
          "Principles of cancer immunotherapy", section on 'Tumor evasion of immune surveillance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">
          "Principles of cancer immunotherapy", section on 'PD-1 and PD ligand 1/2'
         </a>
         .)
        </p>
        <p>
         Treatments are available that target both the PD-1 and PD-L1 molecules, which remove the "brake" on immune surveillance, thereby permitting the body's immune system to recognize and destroy the tumor cells, despite their overexpression of PD-L1 and PD-L2.
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         , therapeutic antibodies targeting PD-1, provide durable antitumor activity in advanced PD-L1-expressing esophagogastric cancer; responses seem to be less frequent (but not absent) in patients with PD-L1-nonexpressing tumors. The issue of using biomarkers such as PD-L1 to predict benefit from PD-1-blocking antibodies is in evolution, and discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'Immunotherapy-based regimens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121739.html" rel="external">
          "Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'PD-L1 overexpression'
         </a>
         .)
        </p>
        <p>
         Results are more consistent for using defective mismatch repair (dMMR) as a biomarker to indicate potential efficacy of immune checkpoint inhibitors. It has been hypothesized that across a wide spectrum of tumors, including gastric cancer, those that lack the mismatch repair mechanism (ie, dMMR) harbor many more mutations (ie, they are hypermutated) than do tumors of the same type without such mismatch repair defects, and that the neoantigens generated from mutations such as these have the potential to be recognized as "non-self" immunogenic antigens. The biologic footprint of dMMR tumors is high levels of microsatellite instability (MSI-H). In fact, patients with metastatic gastric cancer whose tumors are MSI-H or dMMR (but not those with proficient mismatch repair [pMMR] tumors) as well as those with a high tumor mutational burden experience clinical benefit from PD-1 inhibitors, and some responses are durable.
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         is now approved for treatment of advanced disease in a variety of tumor types, including gastric cancer, with either dMMR or high levels of tumor mutational burden. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Clinical efficacy of anti-PD-1 therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121739.html" rel="external">
          "Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'Biomarkers and benefit from PD-1 inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H387852749">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114875.html" rel="external">
          "Society guideline links: Gastric cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3761696572">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric adenocarcinomas represent a clinically, biologically, genetically, and pathologically heterogeneous group of malignant epithelial tumors resulting from various environmental and genetic causes. (See
         <a class="local">
          'Etiology and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Helicobacter pylori
         </em>
         infection plays an important role in gastric carcinogenesis. Gland-forming adenocarcinomas (ie, those of the tubular, papillary, mucinous, and mixed types) are causally related to
         <em>
          H. pylori
         </em>
         and characterized by a defined series of preneoplastic stages, which are not seen with poorly cohesive-type gastric cancers. Importantly, only a small minority of individuals infected with
         <em>
          H. pylori
         </em>
         develops gastric cancer, and it is thought that modulation of the effects of chronic infection by genetic susceptibility, environmental factors, and
         <em>
          H. pylori
         </em>
         bacterial strain differences all influence the evolution into a neoplastic or nonneoplastic process. (See
         <a class="local">
          'Helicobacter pylori'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Familial aggregation of gastric cancer occurs in around 10 to 20 percent of patients with gastric cancer, fewer than 5 percent of cases result from an inherited predisposition to cancer. One of these syndromes, hereditary diffuse gastric cancer (HDGC), is an autosomal dominant cancer susceptibility syndrome characterized by signet ring cell (diffuse) gastric cancer and lobular breast cancer; it is caused in most cases by a germline defect in the
         <em>
          CDH1
         </em>
         (E-cadherin 1) gene. (See
         <a class="local">
          'Hereditary diffuse gastric cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric adenocarcinomas have historically been divided into two distinct histomorphologic subtypes, intestinal (ie, gland-forming) and diffuse (composed of discohesive cells), which have a distinct morphologic appearance, epidemiology, pathogenesis, and genetic profile. The most recent World Health Organization (WHO) classification of tumors of the digestive tract recognizes several important histologic types of malignant epithelial tumors, which include gland-forming types (tubular, papillary mucinous, mixed) and poorly cohesive types (including the signet ring phenotype)  (
         <a class="graphic graphic_table graphicRef129870" href="/z/d/graphic/129870.html" rel="external">
          table 8
         </a>
         ). (See
         <a class="local">
          'World Health Organization classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Broadly, the morphologic differences are attributable to different genetic and epigenetic alterations, some related to intercellular adhesion molecules, which are preserved in intestinal-type tumors and defective in diffuse carcinomas. A lack of adhesion molecules in poorly cohesive carcinomas allows the individual tumor cells to grow and invade neighboring structures without the formation of tubules or glands. Diffuse-type cancers are highly metastatic and characterized by rapid disease progression and a poor prognosis. The main carcinogenic event is loss of expression of
         <em>
          CDH1
         </em>
         , a key cell surface protein for establishing intercellular connections. Biallelic inactivation of the gene encoding E-cadherin
         <em>
         </em>
         (
         <em>
          CDH1
         </em>
         ) can occur through germline or somatic mutation, allelic imbalance events (eg, loss of heterozygosity), or epigenetic silencing of gene transcription. In direct contrast, the pathogenesis of intestinal-type gastric cancers is less well defined. However, it appears to follow a multistep progression that is usually initiated by
         <em>
          H. pylori
         </em>
         infection. (See
         <a class="local">
          'Intestinal versus diffuse types'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several studies have provided unprecedented insight into gastric cancer genome diversity, revealing distinct genome-driven subtypes, novel oncogenic drivers, and candidate biomarkers. This novel taxonomy of gastric adenocarcinomas is critically needed to advance understanding of this deadly disease and tailor treatments as more targeted therapies are developed and approved that, hopefully, will either replace or be used in association with cytotoxic chemotherapy. (See
         <a class="local">
          'Molecular subtyping'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the molecular characterization of gastric cancers as described above has identified gene signatures that are prognostically relevant, they are still inadequate to direct molecularly targeted therapy, with few exceptions. To date, there are only three therapeutically relevant, routinely tested molecular biomarkers in gastric carcinoma: overexpression of human epidermal growth factor 2 (HER2 [ERBB2]), which permits the selection of patients with advanced disease who might benefit from
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         , and overexpression of programmed cell death ligand 1 (PD-L1)/deficient mismatch repair (dMMR), or high levels of tumor mutational burden, all of which may identify patients with advanced disease with the potential to benefit from immune checkpoint inhibitor immunotherapy. (See
         <a class="local">
          'Clinical implications'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Anderson WF, Rabkin CS, Turner N, et al. The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites. J Natl Cancer Inst 2018; 110:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferro A, Peleteiro B, Malvezzi M, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014; 50:1330.
          </a>
         </li>
         <li class="breakAll">
          Cancer Incidence in Five Continents, Curado MP, Edwards B, Shin HR, et al (Eds), IARC Press, Lyon 2007. Vol IX.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 2001; 84:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitani Y, Oue N, Hamai Y, et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J Pathol 2005; 205:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koea JB, Karpeh MS, Brennan MF. Gastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patients. Ann Surg Oncol 2000; 7:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kokkola A, Sipponen P. Gastric carcinoma in young adults. Hepatogastroenterology 2001; 48:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreira H, Pinto-de-Sousa J, Carneiro F, et al. Early onset gastric cancer no longer presents as an advanced disease with ominous prognosis. Dig Surg 2009; 26:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015; 136:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asim M, Chaturvedi R, Piazuelo MB, et al. 542 Helicobacter pylori Strains from a Region of High Gastric Cancer Risk Exhibit Increased Ability to Activate Inducible Nitric Oxide Synthase and Spermine Oxidase. Gastroenterology 2008; 134 (suppl 1):A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solcia E, Fiocca R, Luinetti O, et al. Intestinal and diffuse gastric cancers arise in a different background of Helicobacter pylori gastritis through different gene involvement. Am J Surg Pathol 1996; 20 Suppl 1:S8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiyama A, Maruta F, Ikeno T, et al. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res 1998; 58:2067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe T, Tada M, Nagai H, et al. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998; 115:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52:6735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94:1680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira RM, Machado JC, Figueiredo C. Clinical relevance of Helicobacter pylori vacA and cagA genotypes in gastric carcinoma. Best Pract Res Clin Gastroenterol 2014; 28:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plummer M, van Doorn LJ, Franceschi S, et al. Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions. J Natl Cancer Inst 2007; 99:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González CA, Figueiredo C, Lic CB, et al. Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Am J Gastroenterol 2011; 106:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Omar EM, Carrington M, Chow WH, et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001; 412:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machado JC, Pharoah P, Sousa S, et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001; 121:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyahara R, Niwa Y, Matsuura T, et al. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol 2007; 22:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004; 203:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006; 98:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut 2008; 57:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis. Am J Gastroenterol 2009; 104:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet 1975; 2:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008; 134:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song H, Ekheden IG, Zheng Z, et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ 2015; 351:h3867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Vries AC, Van Driel HF, Richardus JH, et al. Migrant communities constitute a possible target population for primary prevention of Helicobacter pylori-related complications in low incidence countries. Scand J Gastroenterol 2008; 43:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peleteiro B, Bastos J, Barros H, Lunet N. Systematic review of the prevalence of gastric intestinal metaplasia and its area-level association with smoking. Gac Sanit 2008; 22:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filipe MI, Muñoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol 1980; 33:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999; 59:1003.
          </a>
         </li>
         <li class="breakAll">
          Filipe MI, Jass JR. Intestinal metaplasia subtypes and cancer risk. In: Gastric Carcinoma, Churchill Livingstone, London 1986.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filipe MI, Potet F, Bogomoletz WV, et al. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut 1985; 26:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González CA, Sanz-Anquela JM, Gisbert JP, et al. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer 2013; 133:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shao L, Li P, Ye J, et al. Risk of gastric cancer among patients with gastric intestinal metaplasia. Int J Cancer 2018; 143:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991; 32:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubio CA, Jónasson J, Nesi G, et al. Extensive intestinal metaplasia in gastric carcinoma and in other lesions requiring surgery: a study of 3,421 gastrectomy specimens from dwellers of the Atlantic and Pacific basins. J Clin Pathol 2005; 58:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanduleanu S, Jonkers D, de Bruïne A, et al. Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth. Dig Liver Dis 2001; 33:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 2007; 42:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries AC, Haringsma J, de Vries RA, et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc 2009; 70:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 2001; 54:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang KP, Lee HS, Kim N, et al. Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea. J Gastroenterol Hepatol 2009; 24:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith JL, Dixon MF. Is subtyping of intestinal metaplasia in the upper gastrointestinal tract a worthwhile exercise? An evaluation of current mucin histochemical stains. Br J Biomed Sci 2003; 60:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutiérrez-González L, Wright NA. Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. Dig Liver Dis 2008; 40:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenring JR, Nam KT. Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci 2010; 96:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenring JR, Nam KT, Wang TC, et al. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010; 138:2207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt PH, Lee JR, Joshi V, et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 1999; 79:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lennerz JK, Kim SH, Oates EL, et al. The transcription factor MIST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma. Am J Pathol 2010; 177:1514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills JC, Goldenring JR. Metaplasia in the Stomach Arises From Gastric Chief Cells. Cell Mol Gastroenterol Hepatol 2017; 4:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jencks DS, Adam JD, Borum ML, et al. Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer. Gastroenterol Hepatol (N Y) 2018; 14:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sáenz JB, Vargas N, Mills JC. Tropism for Spasmolytic Polypeptide-Expressing Metaplasia Allows Helicobacter pylori to Expand Its Intragastric Niche. Gastroenterology 2019; 156:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sáenz JB, Mills JC. Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer. Nat Rev Gastroenterol Hepatol 2018; 15:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koeppel M, Garcia-Alcalde F, Glowinski F, et al. Helicobacter pylori Infection Causes Characteristic DNA Damage Patterns in Human Cells. Cell Rep 2015; 11:1703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Res 1990; 50:4731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut 1999; 45:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bearzi I, Brancorsini D, Santinelli A, et al. Gastric dysplasia: a ten-year follow-up study. Pathol Res Pract 1994; 190:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi CE, Sonnenberg A, Turner K, Genta RM. High Prevalence of Gastric Preneoplastic Lesions in East Asians and Hispanics in the USA. Dig Dis Sci 2015; 60:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeon SW. Endoscopic management of gastric dysplasia: Cutting edge technology needs a new paradigm. World J Gastrointest Endosc 2010; 2:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn SY, Jang SI, Lee DW, Jeon SW. Gastric endoscopic submucosal dissection is safe for day patients. Clin Endosc 2014; 47:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Hoed CM, Holster IL, Capelle LG, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy 2013; 45:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           You WC, Zhang L, Gail MH, et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000; 92:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000; 92:1881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonnenberg A, Genta RM. Prevalence of benign gastric polyps in a large pathology database. Dig Liver Dis 2015; 47:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stolte M, Vieth M, Ebert MP. High-grade dysplasia in sporadic fundic gland polyps: clinically relevant or not? Eur J Gastroenterol Hepatol 2003; 15:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnason T, Liang WY, Alfaro E, et al. Morphology and natural history of familial adenomatous polyposis-associated dysplastic fundic gland polyps. Histopathology 2014; 65:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrean S, Hering J, Saied A, et al. Gastric adenocarcinoma arising from fundic gland polyps in a patient with familial adenomatous polyposis syndrome. Am Surg 2008; 74:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaib YH, Rugge M, Graham DY, Genta RM. Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol 2013; 11:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfaro EE, Lauwers GY. Early gastric neoplasia: diagnosis and implications. Adv Anat Pathol 2011; 18:268.
          </a>
         </li>
         <li class="breakAll">
          Kushima R, Lauwers GY, Rugge M. Gastric dysplasia. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.71.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Japanese Gastric Cancer Association . Japanese Classification of Gastric Carcinoma - 2nd English Edition -. Gastric Cancer 1998; 1:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000; 24:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter 2007; 12:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jass JR. A classification of gastric dysplasia. Histopathology 1983; 7:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava A, Lauwers GY. Gastric epithelial dysplasia: the Western perspective. Dig Liver Dis 2008; 40:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham SC, Park SJ, Lee JH, et al. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod Pathol 2003; 16:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuello C, López J, Correa P, et al. Histopathology of gastric dysplasias: correlations with gastric juice chemistry. Am J Surg Pathol 1979; 3:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murayama H, Kikuchi M, Enjoji M, et al. Changes in gastric mucosa that antedate gastric carcinoma. Cancer 1990; 66:2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park DY, Srivastava A, Kim GH, et al. Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. Am J Surg Pathol 2008; 32:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valente P, Garrido M, Gullo I, et al. Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness. Gastric Cancer 2015; 18:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agoston AT, Odze RD. Evidence that gastric pit dysplasia-like atypia is a neoplastic precursor lesion. Hum Pathol 2014; 45:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin N, Jo HJ, Kim WK, et al. Gastric pit dysplasia in adjacent gastric mucosa in 414 gastric cancers: prevalence and characteristics. Am J Surg Pathol 2011; 35:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tava F, Luinetti O, Ghigna MR, et al. Type or extension of intestinal metaplasia and immature/atypical "indefinite-for-dysplasia" lesions as predictors of gastric neoplasia. Hum Pathol 2006; 37:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Chang X, Zhou W, et al. Gastric intestinal metaplasia with basal gland atypia: a morphological and biologic evaluation in a large Chinese cohort. Hum Pathol 2013; 44:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li D, Bautista MC, Jiang SF, et al. Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study. Am J Gastroenterol 2016; 111:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raftopoulos SC, Kumarasinghe P, de Boer B, et al. Gastric intraepithelial neoplasia in a Western population. Eur J Gastroenterol Hepatol 2012; 24:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin WS, Kang MW, Kang JH, et al. Epstein-Barr virus-associated gastric adenocarcinomas among Koreans. Am J Clin Pathol 1996; 105:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol 2000; 53:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boysen T, Mohammadi M, Melbye M, et al. EBV-associated gastric carcinoma in high- and low-incidence areas for nasopharyngeal carcinoma. Br J Cancer 2009; 101:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol 2015; 46:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang MS, Uozaki H, Chong JM, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006; 12:2995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kusano M, Toyota M, Suzuki H, et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaneda A, Kaminishi M, Yanagihara K, et al. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002; 62:6645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukayama M, Chong JM, Uozaki H. Pathology and molecular pathology of Epstein-Barr virus-associated gastric carcinoma. Curr Top Microbiol Immunol 2001; 258:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JH, Kim SH, Han SH, et al. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 2009; 24:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009; 137:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Beek J, zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 2004; 22:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Jin H, Cheung KF, et al. Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer. Cancer 2012; 118:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foschi R, Lucenteforte E, Bosetti C, et al. Family history of cancer and stomach cancer risk. Int J Cancer 2008; 123:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015; 16:e60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setia N, Clark JW, Duda DG, et al. Familial Gastric Cancers. Oncologist 2015; 20:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palli D, Galli M, Caporaso NE, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 1994; 3:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzgerald RC, Caldas C. Familial gastric cancer - clinical management. Best Pract Res Clin Gastroenterol 2006; 20:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveira C, Seruca R, Carneiro F. Hereditary gastric cancer. Best Pract Res Clin Gastroenterol 2009; 23:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corso G, Roncalli F, Marrelli D, et al. History, pathogenesis, and management of familial gastric cancer: original study of John XXIII's family. Biomed Res Int 2013; 2013:385132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worthley DL, Phillips KD, Wayte N, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012; 61:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Woods SL, Healey S, et al. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet 2016; 98:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanaru-Fujisawa R, Nakamura S, Moriyama T, et al. Familial fundic gland polyposis with gastric cancer. Gut 2012; 61:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Repak R, Kohoutova D, Podhola M, et al. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature. Gastrointest Endosc 2016; 84:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenner H, Arndt V, Bode G, et al. Risk of gastric cancer among smokers infected with Helicobacter pylori. Int J Cancer 2002; 98:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simán JH, Forsgren A, Berglund G, Florén CH. Tobacco smoking increases the risk for gastric adenocarcinoma among Helicobacter pylori-infected individuals. Scand J Gastroenterol 2001; 36:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Alcohol consumption, smoking and risk of gastric cancer: case-control study from Moscow, Russia. Cancer Causes Control 2000; 11:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferro A, Morais S, Pelucchi C, et al. Smoking and Helicobacter pylori infection: an individual participant pooled analysis (Stomach Cancer Pooling- StoP Project). Eur J Cancer Prev 2019; 28:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epplein M, Nomura AM, Hankin JH, et al. Association of Helicobacter pylori infection and diet on the risk of gastric cancer: a case-control study in Hawaii. Cancer Causes Control 2008; 19:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SA, Kang D, Shim KN, et al. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol 2003; 13:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phukan RK, Narain K, Zomawia E, et al. Dietary habits and stomach cancer in Mizoram, India. J Gastroenterol 2006; 41:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shikata K, Kiyohara Y, Kubo M, et al. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer 2006; 119:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007; 10:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ren JS, Kamangar F, Forman D, Islami F. Pickled food and risk of gastric cancer--a systematic review and meta-analysis of English and Chinese literature. Cancer Epidemiol Biomarkers Prev 2012; 21:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raei N, Behrouz B, Zahri S, Latifi-Navid S. Helicobacter pylori Infection and Dietary Factors Act Synergistically to Promote Gastric Cancer. Asian Pac J Cancer Prev 2016; 17:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viste A, Bjørnestad E, Opheim P, et al. Risk of carcinoma following gastric operations for benign disease. A historical cohort study of 3470 patients. Lancet 1986; 2:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitarz R, Maciejewski R, Polkowski WP, Offerhaus GJ. Gastroenterostoma after Billroth antrectomy as a premalignant condition. World J Gastroenterol 2012; 18:3201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caygill CP, Hill MJ, Hall CN, et al. Increased risk of cancer at multiple sites after gastric surgery for peptic ulcer. Gut 1987; 28:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toftgaard C. Gastric cancer after peptic ulcer surgery. A historic prospective cohort investigation. Ann Surg 1989; 210:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safatle-Ribeiro AV, Ribeiro U Jr, Reynolds JC. Gastric stump cancer: what is the risk? Dig Dis 1998; 16:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tersmette AC, Offerhaus GJ, Tersmette KW, et al. Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer Res 1990; 50:6486.
          </a>
         </li>
         <li class="breakAll">
          Ajani JA, In H, Sano T, et al. Stomach. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.203.
         </li>
         <li>
          <a class="nounderline abstract_t">
           FERNET P, AZAR HA, STOUT AP. INTRAMURAL (TUBAL) SPREAD OF LINITIS PLASTICA ALONG THE ALIMENTARY TRACT. Gastroenterology 1965; 48:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maruyama K, Gunvén P, Okabayashi K, et al. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 1989; 210:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. Curr Opin Gastroenterol 2006; 22:561.
          </a>
         </li>
         <li class="breakAll">
          Borrmann R. Geshwulste des Magens und Duodenums. In: Handbuch der Speziellen Pathologischen Anatomie und Histologie, Henke F, Lubarsch O (Eds), Springer-Verlag, Berlin 1926.
         </li>
         <li>
          <a class="nounderline abstract_t">
           An JY, Kang TH, Choi MG, et al. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg 2008; 12:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo Y, Gao P, Song Y, et al. Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis. World J Surg Oncol 2016; 14:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pan M, Huang P, Li S, et al. Double contrast-enhanced ultrasonography in preoperative Borrmann classification of advanced gastric carcinoma: comparison with histopathology. Sci Rep 2013; 3:3338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dekker W, Tytgat GN. Diagnostic accuracy of fiberendoscopy in the detection of upper intestinal malignancy. A follow-up analysis. Gastroenterology 1977; 73:710.
          </a>
         </li>
         <li class="breakAll">
          Carneiro F, Fukayama M, Grabsch HI, Yasui W. Gastric adenocarcinoma. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.85.
         </li>
         <li>
          <a class="nounderline abstract_t">
           LAUREN P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand 1965; 64:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011; 17:2693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan IB, Ivanova T, Lim KH, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011; 141:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piessen G, Messager M, Leteurtre E, et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009; 250:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribeiro MM, Sarmento JA, Sobrinho Simões MA, Bastos J. Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer 1981; 47:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DY, Park YK, Joo JK, et al. Clinicopathological characteristics of signet ring cell carcinoma of the stomach. ANZ J Surg 2004; 74:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taghavi S, Jayarajan SN, Davey A, Willis AI. Prognostic significance of signet ring gastric cancer. J Clin Oncol 2012; 30:3493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bamboat ZM, Tang LH, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol 2014; 21:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang M, Zhu G, Zhang H, et al. Clinicopathologic features of gastric carcinoma with signet ring cell histology. J Gastrointest Surg 2010; 14:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunisaki C, Shimada H, Nomura M, et al. Therapeutic strategy for signet ring cell carcinoma of the stomach. Br J Surg 2004; 91:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyung WJ, Noh SH, Lee JH, et al. Early gastric carcinoma with signet ring cell histology. Cancer 2002; 94:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chon HJ, Hyung WJ, Kim C, et al. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Ann Surg 2017; 265:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 2003; 14:1705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charlton A, Blair V, Shaw D, et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004; 53:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999; 8:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chun YS, Lindor NM, Smyrk TC, et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 2001; 92:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006; 4:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007; 245:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber ME, Save V, Carneiro F, et al. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 2008; 216:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humar B, Graziano F, Cascinu S, et al. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 2002; 21:8192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-de la Medina A, More H, Medina-Franco H, et al. Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer. Rev Esp Enferm Dig 2006; 98:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000; 26:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 2013; 31:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe H, Enjoji M, Imai T. Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer 1976; 38:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim H, Park YS, Lee JH, et al. Features of Gastric Carcinoma With Lymphoid Stroma Associated With Epstein-Barr Virus. Clin Gastroenterol Hepatol 2015; 13:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang HH, Wu MS, Shun CT, et al. Lymphoepithelioma-like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein-Barr virus infection. Hepatogastroenterology 1999; 46:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park S, Choi MG, Kim KM, et al. Lymphoepithelioma-like carcinoma: a distinct type of gastric cancer. J Surg Res 2015; 194:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiaravalli AM, Cornaggia M, Furlan D, et al. The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage. Virchows Arch 2001; 439:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng N, Hui DY, Liu Y, et al. Is gastric lymphoepithelioma-like carcinoma a special subtype of EBV-associated gastric carcinoma? New insight based on clinicopathological features and EBV genome polymorphisms. Gastric Cancer 2015; 18:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukayama M, Ushiku T. Epstein-Barr virus-associated gastric carcinoma. Pathol Res Pract 2011; 207:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minamoto T, Mai M, Watanabe K, et al. Medullary carcinoma with lymphocytic infiltration of the stomach. Clinicopathologic study of 27 cases and immunohistochemical analysis of the subpopulations of infiltrating lymphocytes in the tumor. Cancer 1990; 66:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song HJ, Kim KM. Pathology of epstein-barr virus-associated gastric carcinoma and its relationship to prognosis. Gut Liver 2011; 5:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto N, Tokunaga M, Uemura Y, et al. Epstein-Barr virus and gastric remnant cancer. Cancer 1994; 74:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsunou H, Konishi F, Hori H, et al. Characteristics of Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma in Japan. Cancer 1996; 77:1998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tak DH, Jeong HY, Seong JK, et al. [Comparison of clinical characteristics and prognostic factors between gastric lymphoepithelioma-like carcinoma and gastric adenocarcinoma]. Korean J Gastroenterol 2013; 62:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camargo MC, Kim WH, Chiaravalli AM, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 2014; 63:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu MS, Shun CT, Wu CC, et al. Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology 2000; 118:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma C, Patel K, Singhi AD, et al. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. Am J Surg Pathol 2016; 40:1496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito R, Abe H, Kunita A, et al. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol 2017; 30:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panda A, Mehnert JM, Hirshfield KM, et al. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. J Natl Cancer Inst 2018; 110:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori M, Iwashita A, Enjoji M. Adenosquamous carcinoma of the stomach. A clinicopathologic analysis of 28 cases. Cancer 1986; 57:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Shen C, Yin R, et al. Clinicopathological characteristics, diagnosis, treatment, and outcomes of primary gastric adenosquamous carcinoma. World J Surg Oncol 2015; 13:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BOSWELL JT, HELWIG EB. SQUAMOUS CELL CARCINOMA AND ADENOACANTHOMA OF THE STOMACH. A CLINICOPATHOLOGIC STUDY. Cancer 1965; 18:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnheim DC, Sarac OK, Fett W. Primary squamous cell carcinoma of the stomach. Am J Gastroenterol 1985; 80:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marubashi S, Yano H, Monden T, et al. Primary squamous cell carcinoma of the stomach. Gastric Cancer 1999; 2:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eom DW, Kang GH, Han SH, et al. Gastric micropapillary carcinoma: A distinct subtype with a significantly worse prognosis in TNM stages I and II. Am J Surg Pathol 2011; 35:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Q, Ming J, Zhang S, et al. Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis. Gastric Cancer 2015; 18:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ushiku T, Matsusaka K, Iwasaki Y, et al. Gastric carcinoma with invasive micropapillary pattern and its association with lymph node metastasis. Histopathology 2011; 59:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita T, Gotohda N, Kato Y, et al. Clinicopathological features of stomach cancer with invasive micropapillary component. Gastric Cancer 2012; 15:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueyama H, Yao T, Nakashima Y, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol 2010; 34:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohda G, Osawa T, Asada Y, et al. Gastric adenocarcinoma of fundic gland type: Endoscopic and clinicopathological features. World J Gastrointest Endosc 2016; 8:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiba T, Kato K, Masuda T, et al. Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings. Dig Endosc 2016; 28:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhi AD, Lazenby AJ, Montgomery EA. Gastric adenocarcinoma with chief cell differentiation: a proposal for reclassification as oxyntic gland polyp/adenoma. Am J Surg Pathol 2012; 36:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan K, Brown IS, Kyle T, et al. Chief cell-predominant gastric polyps: a series of 12 cases with literature review. Histopathology 2016; 68:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali SM, Sanford EM, Klempner SJ, et al. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist 2015; 20:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanazono K, Natsugoe S, Stein HJ, et al. Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression. Oncol Rep 2006; 15:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015; 21:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei Z, Tan IB, Das K, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013; 145:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishizawa T, Nakano K, Harada A, et al. DGC-specific RHOA mutations maintained cancer cell survival and promoted cell migration via ROCK inactivation. Oncotarget 2018; 9:23198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakayama I, Shinozaki E, Sakata S, et al. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults. Cancer Sci 2019; 110:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao F, Kausalya JP, Sia YY, et al. Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity. Cell Rep 2015; 12:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada T, Kuramitsu K, Rikitsu E, et al. Nectin and junctional adhesion molecule are critical cell adhesion molecules for the apico-basal alignment of adherens and tight junctions in epithelial cells. Genes Cells 2013; 18:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleisher AS, Esteller M, Wang S, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gylling A, Abdel-Rahman WM, Juhola M, et al. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut 2007; 56:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohn BH, Hwang JE, Jang HJ, et al. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res 2017; 23:4441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alessandrini L, Manchi M, De Re V, et al. Proposed Molecular and miRNA Classification of Gastric Cancer. Int J Mol Sci 2018; 19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol 2013; 8:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011; 11:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 2016; 140:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pectasides E, Stachler MD, Derks S, et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 2018; 8:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilous M, Osamura RY, Rüschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2010; 41:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox SB, Kumarasinghe MP, Armes JE, et al. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol 2012; 36:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104:1372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong DD, Kumarasinghe MP, Platten MA, de Boer WB. Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers. Pathology 2015; 47:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013; 49:1448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park SR, Park YS, Ryu MH, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer 2016; 53:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warneke VS, Behrens HM, Böger C, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 2013; 24:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rüschoff J, Nagelmeier I, Baretton G, et al. [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe 2010; 31:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee S, de Boer WB, Fermoyle S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao J, Bedell V, Lee J, et al. Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival. JAMA Netw Open 2020; 3:e203652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinozaki E, Yamamoto N, Chin K, et al. How many biopsy fragments will be necessary to assess HER2 status for gastric cancer? J Clin Oncol 2012; 30:40 (suppl).
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn S, Ahn S, Van Vrancken M, et al. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget 2015; 6:38372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 2012; 43:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haffner I, Schierle K, Raimúndez E, et al. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. J Clin Oncol 2021; 39:1468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 119517 Version 11.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29361173" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24650579" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24650579" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16404738" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The global health burden of infection-associated cancers in the year 2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11161407" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15586362" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10864341" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Gastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11813570" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Gastric carcinoma in young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19468231" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Early onset gastric cancer no longer presents as an advanced disease with ominous prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24889903" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Global burden of gastric cancer attributable to Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : 542 Helicobacter pylori Strains from a Region of High Gastric Cancer Risk Exhibit Increased Ability to Activate Inducible Nitric Oxide Synthase and Spermine Oxidase
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8694148" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Intestinal and diffuse gastric cancers arise in a different background of Helicobacter pylori gastritis through different gene involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9605743" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9721161" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Helicobacter pylori infection induces gastric cancer in mongolian gerbils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1458460" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11556297" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Helicobacter pylori infection and the development of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441323" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25439067" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Clinical relevance of Helicobacter pylori vacA and cagA genotypes in gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17728213" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21285949" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10746728" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Interleukin-1 polymorphisms associated with increased risk of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11808612" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11606496" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12730860" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12891537" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17573829" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15141383" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17047193" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17895354" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19174811" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/49653" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A model for gastric cancer epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18395075" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26215280" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18365904" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Migrant communities constitute a possible target population for primary prevention of Helicobacter pylori-related complications in low incidence countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18579050" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Systematic review of the prevalence of gastric intestinal metaplasia and its area-level association with smoking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18424244" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : OLGA staging for gastritis: a tutorial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8168991" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7430392" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Role of intestinal metaplasia in the histogenesis of gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10070955" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10070955" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4085908" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23280711" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29707766" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Risk of gastric cancer among patients with gastric intestinal metaplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1955163" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16311346" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Extensive intestinal metaplasia in gastric carcinoma and in other lesions requiring surgery: a study of 3,421 gastrectomy specimens from dwellers of the Atlantic and Pacific basins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11785719" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17190755" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19249770" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22198778" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11533073" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Gastric intestinal metaplasia: subtypes and natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18713298" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14725332" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Is subtyping of intestinal metaplasia in the upper gastrointestinal tract a worthwhile exercise? An evaluation of current mucin histochemical stains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18400571" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21075342" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Oxyntic atrophy, metaplasia, and gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20450866" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10378506" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20709804" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The transcription factor MIST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28560292" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Metaplasia in the Stomach Arises From Gastric Chief Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29606921" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30287170" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Tropism for Spasmolytic Polypeptide-Expressing Metaplasia Allows Helicobacter pylori to Expand Its Intragastric Niche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29463907" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26074077" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Helicobacter pylori Infection Causes Characteristic DNA Damage Patterns in Human Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2369747" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Gastric precancerous process in a high risk population: cross-sectional studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10517922" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Gastric epithelial dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8065990" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Gastric dysplasia: a ten-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25724165" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : High Prevalence of Gastric Preneoplastic Lesions in East Asians and Hispanics in the USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21160760" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Endoscopic management of gastric dysplasia: Cutting edge technology needs a new paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25505720" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Gastric endoscopic submucosal dissection is safe for day patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23533073" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Follow-up of premalignant lesions in patients at risk for progression to gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11018097" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11106679" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25458775" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prevalence of benign gastric polyps in a large pathology database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18237868" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Fundic gland polyp dysplasia is common in familial adenomatous polyposis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14560146" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : High-grade dysplasia in sporadic fundic gland polyps: clinically relevant or not?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24548295" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Morphology and natural history of familial adenomatous polyposis-associated dysplastic fundic gland polyps.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18274437" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Gastric adenocarcinoma arising from fundic gland polyps in a patient with familial adenomatous polyposis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23583466" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Management of gastric polyps: an endoscopy-based approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21654358" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Early gastric neoplasia: diagnosis and implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21654358" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Early gastric neoplasia: diagnosis and implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11957040" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Japanese Classification of Gastric Carcinoma - 2nd English Edition -
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10680883" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Gastric dysplasia: the Padova international classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10896917" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The Vienna classification of gastrointestinal epithelial neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17241295" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6852781" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A classification of gastric dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18424243" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Gastric epithelial dysplasia: the Western perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12920223" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/534386" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Histopathology of gastric dysplasias: correlations with gastric juice chemistry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1699656" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Changes in gastric mucosa that antedate gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18300795" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25146833" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24529328" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Evidence that gastric pit dysplasia-like atypia is a neoplastic precursor lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21677540" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Gastric pit dysplasia in adjacent gastric mucosa in 414 gastric cancers: prevalence and characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16949645" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Type or extension of intestinal metaplasia and immature/atypical "indefinite-for-dysplasia" lesions as predictors of gastric neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23079203" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Gastric intestinal metaplasia with basal gland atypia: a morphological and biologic evaluation in a large Chinese cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27185078" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22081007" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Gastric intraepithelial neoplasia in a Western population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8607441" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Epstein-Barr virus-associated gastric adenocarcinomas among Koreans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11091849" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Epstein-Barr virus and gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19603026" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : EBV-associated gastric carcinoma in high- and low-incidence areas for nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25633561" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Update on Epstein-Barr virus and gastric cancer (review).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16707594" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16518809" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12438262" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Identification of silencing of nine genes in human gastric cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11443869" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Pathology and molecular pathology of Epstein-Barr virus-associated gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19335785" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19445939" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14966089" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21717425" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18567000" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Family history of cancer and stomach cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25638682" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Familial gastric cancer: genetic susceptibility, pathology, and implications for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26424758" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Familial Gastric Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8118379" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Family history and risk of stomach cancer in Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16997157" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Familial gastric cancer - clinical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19414142" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Hereditary gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25979631" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23484115" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : History, pathogenesis, and management of familial gastric cancer: original study of John XXIII's family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21813476" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27087319" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22027476" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Familial fundic gland polyposis with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27343414" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11920598" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Risk of gastric cancer among smokers infected with Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11252415" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Tobacco smoking increases the risk for gastric adenocarcinoma among Helicobacter pylori-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10843447" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Alcohol consumption, smoking and risk of gastric cancer: case-control study from Moscow, Russia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30272597" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Smoking and Helicobacter pylori infection: an individual participant pooled analysis (Stomach Cancer Pooling- StoP Project).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18369531" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Association of Helicobacter pylori infection and diet on the risk of gastric cancer: a case-control study in Hawaii.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12749604" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16799882" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Dietary habits and stomach cancer in Mizoram, India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16450397" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17577615" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Diet and the risk of gastric cancer: review of epidemiological evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22499775" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Pickled food and risk of gastric cancer--a systematic review and meta-analysis of English and Chinese literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27039812" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Helicobacter pylori Infection and Dietary Factors Act Synergistically to Promote Gastric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2875248" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Risk of carcinoma following gastric operations for benign disease. A historical cohort study of 3470 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22783043" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Gastroenterostoma after Billroth antrectomy as a premalignant condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3666558" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Increased risk of cancer at multiple sites after gastric surgery for peptic ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2757419" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Gastric cancer after peptic ulcer surgery. A historic prospective cohort investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9618135" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Gastric stump cancer: what is the risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2145061" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2145061" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14275076" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : INTRAMURAL (TUBAL) SPREAD OF LINITIS PLASTICA ALONG THE ALIMENTARY TRACT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2818028" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Lymph node metastases of gastric cancer. General pattern in 1931 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16891890" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Endoscopic resection of early gastric cancer: the Japanese perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16891890" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Endoscopic resection of early gastric cancer: the Japanese perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18516653" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Borrmann type IV: an independent prognostic factor for survival in gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26912240" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24275807" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Double contrast-enhanced ultrasonography in preoperative Borrmann classification of advanced gastric carcinoma: comparison with histopathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/892375" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Diagnostic accuracy of fiberendoscopy in the detection of upper intestinal malignancy. A follow-up analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/892375" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Diagnostic accuracy of fiberendoscopy in the detection of upper intestinal malignancy. A follow-up analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14320675" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21430069" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Molecular classification of gastric cancer: a new paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21684283" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19855261" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7226025" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15574148" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Clinicopathological characteristics of signet ring cell carcinoma of the stomach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22927530" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Prognostic significance of signet ring gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24394986" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20033340" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Clinicopathologic features of gastric carcinoma with signet ring cell histology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15376179" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Therapeutic strategy for signet ring cell carcinoma of the stomach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11815962" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Early gastric carcinoma with signet ring cell histology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27232252" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630673" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15138207" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10072428" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11443625" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16527687" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Hereditary diffuse gastric cancer: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17522512" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18825658" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12444556" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16555931" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10973239" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749913" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23341533" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/947518" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25912839" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Features of Gastric Carcinoma With Lymphoid Stroma Associated With Epstein-Barr Virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10370694" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Lymphoepithelioma-like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein-Barr virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25592274" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Lymphoepithelioma-like carcinoma: a distinct type of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11561756" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24771002" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Is gastric lymphoepithelioma-like carcinoma a special subtype of EBV-associated gastric carcinoma? New insight based on clinicopathological features and EBV genome polymorphisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15510157" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Epstein-Barr virus: 40 years on.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21944426" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Epstein-Barr virus-associated gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2386921" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Medullary carcinoma with lymphocytic infiltration of the stomach. Clinicopathologic study of 27 cases and immunohistochemical analysis of the subpopulations of infiltrating lymphocytes in the tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21814592" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Pathology of epstein-barr virus-associated gastric carcinoma and its relationship to prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8039108" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Epstein-Barr virus and gastric remnant cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8640662" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Characteristics of Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24262592" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : [Comparison of clinical characteristics and prognostic factors between gastric lymphoepithelioma-like carcinoma and gastric adenocarcinoma].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23580779" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10833477" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27465786" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27934877" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25079317" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Comprehensive molecular characterization of gastric adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29155997" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3942965" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Adenosquamous carcinoma of the stomach. A clinicopathologic analysis of 28 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25889482" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Clinicopathological characteristics, diagnosis, treatment, and outcomes of primary gastric adenosquamous carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14254074" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : SQUAMOUS CELL CARCINOMA AND ADENOACANTHOMA OF THE STOMACH. A CLINICOPATHOLOGIC STUDY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3970006" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Primary squamous cell carcinoma of the stomach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11957086" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Primary squamous cell carcinoma of the stomach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21164291" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Gastric micropapillary carcinoma: A distinct subtype with a significantly worse prognosis in TNM stages I and II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24562421" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22175888" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Gastric carcinoma with invasive micropapillary pattern and its association with lymph node metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21987353" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Clinicopathological features of stomach cancer with invasive micropapillary component.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20410811" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962407" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Gastric adenocarcinoma of fundic gland type: Endoscopic and clinicopathological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27129734" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22472957" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Gastric adenocarcinoma with chief cell differentiation: a proposal for reclassification as oxyntic gland polyp/adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26335020" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Chief cell-predominant gastric polyps: a series of 12 cases with literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23770567" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Mutational heterogeneity in cancer and the search for new cancer-associated genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25882375" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16525665" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25894828" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23684942" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29796182" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : DGC-specific RHOA mutations maintained cancer cell survival and promoted cell migration via ROCK inactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30771244" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26146084" id="rid211" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          212 : Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24112238" id="rid212" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          213 : Nectin and junctional adhesion molecule are critical cell adhesion molecules for the apico-basal alignment of adherens and tight junctions in epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3012781" id="rid213" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          214 : The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10070967" id="rid214" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          215 : Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17267619" id="rid215" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          216 : Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28747339" id="rid216" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          217 : Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29882766" id="rid217" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          218 : Proposed Molecular and miRNA Classification of Gastric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20728210" id="rid218" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          219 : Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23656792" id="rid219" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          220 : HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21342044" id="rid220" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          221 : HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27841667" id="rid221" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          222 : HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28978556" id="rid222" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          223 : Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18422971" id="rid223" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          224 : Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20665045" id="rid224" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          225 : HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21169738" id="rid225" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          226 : HER2 testing in gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19914678" id="rid226" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          227 : HER-2 amplification is highly homogenous in gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22314190" id="rid227" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          228 : Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22092393" id="rid228" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          229 : Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21487407" id="rid229" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          230 : Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26517644" id="rid230" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          231 : Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23146959" id="rid231" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          232 : Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26693898" id="rid232" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          233 : Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23139264" id="rid233" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          234 : Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20443098" id="rid234" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          235 : [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22092394" id="rid235" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          236 : Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32338752" id="rid236" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          237 : Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid237" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          238 : How many biopsy fragments will be necessary to assess HER2 status for gastric cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26460823" id="rid238" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          239 : Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21855114" id="rid239" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          240 : Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16328035" id="rid240" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          241 : Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33764808" id="rid241" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          242 : HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22658127" id="rid242" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          243 : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22658128" id="rid243" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          244 : Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
